

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 1 and this is page value 2: 1

Body System or Organ Class	Dictionary-Derived Term	Placebo		Xanomeline		Total (N=254)	
		n	(%)	n	(%)		
ANY EVENT	ANY EVENT	69	(80%)	86	(90%)	70 (97%)	225 (89%)
CARDIAC DISORDERS	ANY EVENT	13	(15%)	16	(17%)	15 (21%)	44 (17%)
	ATRIAL FIBRILLATION	1	(1%)	2	(2%)	2 (3%)	5 (2%)
	ATRIAL FLUTTER	0	(0%)	1	(1%)	1 (1%)	2 (1%)
	ATRIAL HYPERTROPHY	1	(1%)	0	(0%)	0 (0%)	1 (0%)
	ATRIOVENTRICULAR BLOCK	1	(1%)	1	(1%)	0 (0%)	2 (1%)
	FIRST DEGREE						
	ATRIOVENTRICULAR BLOCK	2	(2%)	2	(2%)	1 (1%)	5 (2%)
	SECOND DEGREE						
	BRADYCARDIA	1	(1%)	0	(0%)	0 (0%)	1 (0%)
	BUNDLE BRANCH BLOCK	1	(1%)	0	(0%)	0 (0%)	1 (0%)
	LEFT						
	BUNDLE BRANCH BLOCK	1	(1%)	1	(1%)	0 (0%)	2 (1%)
	RIGHT						
	CARDIAC DISORDER	0	(0%)	0	(0%)	1 (1%)	1 (0%)
	CARDIAC FAILURE	1	(1%)	0	(0%)	0 (0%)	1 (0%)
	CONGESTIVE						
	MYOCARDIAL INFARCTION	4	(5%)	2	(2%)	4 (6%)	10 (4%)
	PALPITATIONS	0	(0%)	2	(2%)	0 (0%)	2 (1%)
	SINUS ARRHYTHMIA	1	(1%)	0	(0%)	0 (0%)	1 (0%)
	SINUS BRADYCARDIA	2	(2%)	7	(7%)	8 (11%)	17 (7%)
	SUPRAVENTRICULAR						
	EXTRASYSTOLES	1	(1%)	1	(1%)	1 (1%)	3 (1%)

- 1.) Only treatment emergent events related to lipids are displayed.  
 2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 1 and this is page value 2: 1

Body System or Organ Class	Dictionary-Derived Term	Placebo	Xanomeline	Xanomeline	Total
		(N=86) n (%)	Low Dose (N=96) n (%)	High Dose (N=72) n (%)	(N=254) n (%)
CARDIAC DISORDERS	SUPRAVENTRICULAR TACHYCARDIA	0 (0%)	1 (1%)	0 (0%)	1 (0%)
	TACHYCARDIA	1 (1%)	0 (0%)	0 (0%)	1 (0%)
	VENTRICULAR EXTRASYSTOLES	0 (0%)	2 (2%)	1 (1%)	3 (1%)
	VENTRICULAR HYPERTROPHY	1 (1%)	0 (0%)	0 (0%)	1 (0%)
	WOLFF-PARKINSON-WHITE SYNDROME	0 (0%)	1 (1%)	0 (0%)	1 (0%)
CONGENITAL, FAMILIAL AND GENETIC DISORDERS	ANY EVENT	0 (0%)	1 (1%)	2 (3%)	3 (1%)
	VENTRICULAR SEPTAL DEFECT	0 (0%)	1 (1%)	2 (3%)	3 (1%)
EAR AND LABYRINTH DISORDERS	ANY EVENT	1 (1%)	2 (2%)	1 (1%)	4 (2%)
	CERUMEN IMPACTION	0 (0%)	1 (1%)	0 (0%)	1 (0%)
	EAR PAIN	1 (1%)	0 (0%)	0 (0%)	1 (0%)
	TINNITUS	0 (0%)	1 (1%)	0 (0%)	1 (0%)
	VERTIGO	0 (0%)	1 (1%)	1 (1%)	2 (1%)
EYE DISORDERS	ANY EVENT	4 (5%)	2 (2%)	1 (1%)	7 (3%)
	CONJUNCTIVAL HAEMORRHAGE	0 (0%)	1 (1%)	0 (0%)	1 (0%)

- 1.) Only treatment emergent events related to lipids are displayed.
- 2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 1 and this is page value 2: 1

Body System or Organ Class	Dictionary-Derived Term	Placebo		Xanomeline		Total (N=254)			
		(N=86)		Low Dose (N=96)					
		n	(%)	n	(%)				
EYE DISORDERS	CONJUNCTIVITIS	2	(2%)	0	(0%)	0	(0%)	2	(1%)
	EYE ALLERGY	1	(1%)	0	(0%)	0	(0%)	1	(0%)
	EYE PRURITUS	1	(1%)	0	(0%)	0	(0%)	1	(0%)
	EYE SWELLING	1	(1%)	0	(0%)	0	(0%)	1	(0%)
	GLAUCOMA	1	(1%)	0	(0%)	0	(0%)	1	(0%)
	VISION BLURRED	0	(0%)	1	(1%)	1	(1%)	2	(1%)
GASTROINTESTINAL DISORDERS	ANY EVENT	17	(20%)	16	(17%)	20	(28%)	53	(21%)
	ABDOMINAL DISCOMFORT	0	(0%)	0	(0%)	1	(1%)	1	(0%)
	ABDOMINAL PAIN	1	(1%)	3	(3%)	1	(1%)	5	(2%)
	CONSTIPATION	1	(1%)	0	(0%)	0	(0%)	1	(0%)
	DIARRHOEA	9	(10%)	6	(6%)	3	(4%)	18	(7%)
	DYSPEPSIA	1	(1%)	1	(1%)	1	(1%)	3	(1%)
	DYSPHAGIA	0	(0%)	1	(1%)	0	(0%)	1	(0%)
	FLATULENCE	1	(1%)	0	(0%)	0	(0%)	1	(0%)
	GASTROINTESTINAL HAEMORRHAGE	0	(0%)	0	(0%)	1	(1%)	1	(0%)
	GASTROOESOPHAGEAL REFLUX DISEASE	1	(1%)	0	(0%)	0	(0%)	1	(0%)
	GLOSSITIS	1	(1%)	0	(0%)	0	(0%)	1	(0%)
	HIATUS HERNIA	1	(1%)	0	(0%)	0	(0%)	1	(0%)
	NAUSEA	3	(3%)	3	(3%)	6	(8%)	12	(5%)
	RECTAL HAEMORRHAGE	0	(0%)	1	(1%)	0	(0%)	1	(0%)

- 1.) Only treatment emergent events related to lipids are displayed.
- 2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 1 and this is page value 2: 1

Body System or Organ Class	Dictionary-Derived Term	Placebo		Xanomeline		Total (N=254)	
		(N=86)		Low Dose (N=96)			
		n	(%)	n	(%)		
GASTROINTESTINAL DISORDERS	SALIVARY HYPERSECRETION	0	(0%)	0	(0%)	4 (6%)	
	STOMACH DISCOMFORT	0	(0%)	0	(0%)	1 (1%)	
	VOMITING	3	(3%)	4	(4%)	6 (8%)	
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	ANY EVENT	21	(24%)	51	(53%)	36 (50%)	
	APPLICATION SITE BLEEDING	0	(0%)	1	(1%)	0 (0%)	
	APPLICATION SITE DERMATITIS	5	(6%)	9	(9%)	7 (10%)	
	APPLICATION SITE DESQUAMATION	0	(0%)	1	(1%)	0 (0%)	
	APPLICATION SITE DISCHARGE	0	(0%)	0	(0%)	1 (1%)	
	APPLICATION SITE DISCOLOURATION	0	(0%)	1	(1%)	0 (0%)	
	APPLICATION SITE ERYTHEMA	3	(3%)	13	(14%)	14 (19%)	
	APPLICATION SITE INDURATION	1	(1%)	0	(0%)	0 (0%)	
	APPLICATION SITE IRRITATION	3	(3%)	9	(9%)	9 (12%)	
						21 (8%)	

1.) Only treatment emergent events related to lipids are displayed.

2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 1 and this is page value 2: 1

Body System or Organ Class	Dictionary-Derived Term	Placebo (N=86)		Xanomeline Low Dose (N=96)		Xanomeline High Dose (N=72)		Total (N=254)
		n	(%)	n	(%)	n	(%)	
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	APPLICATION SITE PAIN	0	(0%)	0	(0%)	2	(3%)	2 (1%)
	APPLICATION SITE PERSPIRATION	0	(0%)	0	(0%)	2	(3%)	2 (1%)
	APPLICATION SITE PRURITUS	6	(7%)	23	(24%)	21	(29%)	50 (20%)
	APPLICATION SITE REACTION	1	(1%)	0	(0%)	1	(1%)	2 (1%)
	APPLICATION SITE SWELLING	0	(0%)	1	(1%)	2	(3%)	3 (1%)
	APPLICATION SITE URTICARIA	0	(0%)	2	(2%)	1	(1%)	3 (1%)
	APPLICATION SITE VESICLES	1	(1%)	5	(5%)	5	(7%)	11 (4%)
	APPLICATION SITE WARMTH	0	(0%)	1	(1%)	0	(0%)	1 (0%)
	ASTHENIA	1	(1%)	1	(1%)	0	(0%)	2 (1%)
	CHEST DISCOMFORT	0	(0%)	1	(1%)	1	(1%)	2 (1%)
	CHEST PAIN	0	(0%)	0	(0%)	2	(3%)	2 (1%)
	CHILLS	1	(1%)	1	(1%)	1	(1%)	3 (1%)

- 1.) Only treatment emergent events related to lipids are displayed.
- 2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 1 and this is page value 2: 1

Body System or Organ Class	Dictionary-Derived Term	Placebo		Xanomeline		Xanomeline		Total (N=254)	
		(N=86)		Low Dose (N=96)		High Dose (N=72)			
		n	(%)	n	(%)	n	(%)		
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	CYST	0	(0%)	1	(1%)	0	(0%)	1 (0%)	
	FATIGUE	1	(1%)	5	(5%)	5	(7%)	11 (4%)	
	FEELING ABNORMAL	0	(0%)	0	(0%)	1	(1%)	1 (0%)	
	FEELING COLD	0	(0%)	0	(0%)	1	(1%)	1 (0%)	
	INFLAMMATION	0	(0%)	1	(1%)	0	(0%)	1 (0%)	
	MALAISE	0	(0%)	1	(1%)	2	(3%)	3 (1%)	
	OEDEMA	0	(0%)	2	(2%)	0	(0%)	2 (1%)	
	OEDEMA PERIPHERAL	2	(2%)	1	(1%)	2	(3%)	5 (2%)	
	PAIN	0	(0%)	1	(1%)	1	(1%)	2 (1%)	
	PYREXIA	2	(2%)	1	(1%)	0	(0%)	3 (1%)	
	SECRETION DISCHARGE	0	(0%)	1	(1%)	0	(0%)	1 (0%)	

1.) Only treatment emergent events related to lipids are displayed.

2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 1 and this is page value 2: 1

Body System or Organ Class	Dictionary-Derived Term	Placebo		Xanomeline		Total (N=254)	
		(N=86)		Low Dose (N=96)			
		n	(%)	n	(%)		
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	SUDDEN DEATH	0	(0%)	1	(1%)	0 (0%)	
	SWELLING	0	(0%)	1	(1%)	0 (0%)	
	ULCER	0	(0%)	1	(1%)	0 (0%)	
HEPATOBILIARY DISORDERS	ANY EVENT	1	(1%)	0	(0%)	0 (0%)	
	HYPERBILIRUBINAEMIA	1	(1%)	0	(0%)	0 (0%)	
IMMUNE SYSTEM DISORDERS	ANY EVENT	0	(0%)	1	(1%)	1 (0%)	
	HYPERSENSITIVITY	0	(0%)	1	(1%)	0 (0%)	
	SEASONAL ALLERGY	0	(0%)	0	(0%)	1 (0%)	
INFECTIONS AND INFESTATIONS	ANY EVENT	16	(19%)	10	(10%)	13 (18%)	
	BRONCHITIS	1	(1%)	0	(0%)	0 (0%)	
	CELLULITIS	0	(0%)	1	(1%)	0 (0%)	
	CERVICITIS	1	(1%)	0	(0%)	0 (0%)	
	CYSTITIS	1	(1%)	0	(0%)	1 (1%)	
	EAR INFECTION	2	(2%)	0	(0%)	0 (0%)	
	GASTROENTERITIS VIRAL	1	(1%)	0	(0%)	0 (0%)	
	HORDEOLUM	0	(0%)	0	(0%)	1 (1%)	
	INFLUENZA	1	(1%)	1	(1%)	1 (1%)	

- 1.) Only treatment emergent events related to lipids are displayed.
- 2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 1 and this is page value 2: 1

Body System or Organ Class	Dictionary-Derived Term	Placebo (N=86)		Xanomeline Low Dose (N=96)		Xanomeline High Dose (N=72)		Total (N=254) n (%)
		n	(%)	n	(%)	n	(%)	
INFECTIONS AND INFESTATIONS	LOCALISED INFECTION	1	(1%)	1	(1%)	0	(0%)	2 (1%)
	LOWER RESPIRATORY TRACT INFECTION	0	(0%)	0	(0%)	1	(1%)	1 (0%)
	NASOPHARYNGITIS	2	(2%)	4	(4%)	6	(8%)	12 (5%)
	ONYCHOMYCOSIS	0	(0%)	1	(1%)	0	(0%)	1 (0%)
	PNEUMONIA	0	(0%)	1	(1%)	0	(0%)	1 (0%)
	RHINITIS	0	(0%)	0	(0%)	1	(1%)	1 (0%)
	UPPER RESPIRATORY TRACT INFECTION	6	(7%)	1	(1%)	3	(4%)	10 (4%)
	URINARY TRACT INFECTION	2	(2%)	0	(0%)	1	(1%)	3 (1%)
	VAGINAL MYCOSIS	1	(1%)	0	(0%)	0	(0%)	1 (0%)
	VIRAL INFECTION	0	(0%)	1	(1%)	0	(0%)	1 (0%)
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	ANY EVENT	4	(5%)	5	(5%)	5	(7%)	14 (6%)
	CONTUSION	1	(1%)	1	(1%)	2	(3%)	4 (2%)
	EXCORIATION	2	(2%)	1	(1%)	1	(1%)	4 (2%)
	FACIAL BONES FRACTURE	0	(0%)	0	(0%)	1	(1%)	1 (0%)
	FALL	1	(1%)	2	(2%)	1	(1%)	4 (2%)

1.) Only treatment emergent events related to lipids are displayed.

2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 1 and this is page value 2: 1

Body System or Organ Class	Dictionary-Derived Term	Placebo	Xanomeline Low Dose	Xanomeline High Dose	Total
		(N=86) n (%)	(N=96) n (%)	(N=72) n (%)	(N=254) n (%)
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	HIP FRACTURE	1 (1%)	0 (0%)	2 (3%)	3 (1%)
	JOINT DISLOCATION	0 (0%)	1 (1%)	0 (0%)	1 (0%)
	SKIN LACERATION	1 (1%)	2 (2%)	0 (0%)	3 (1%)
	WOUND	0 (0%)	1 (1%)	0 (0%)	1 (0%)
INVESTIGATIONS	ANY EVENT	10 (12%)	8 (8%)	5 (7%)	23 (9%)
	BIOPSY	0 (0%)	0 (0%)	1 (1%)	1 (0%)
	BIOPSY PROSTATE	0 (0%)	0 (0%)	1 (1%)	1 (0%)
	BLOOD ALKALINE	1 (1%)	0 (0%)	0 (0%)	1 (0%)
	PHOSPHATASE INCREASED				
	BLOOD CHOLESTEROL	0 (0%)	0 (0%)	1 (1%)	1 (0%)
	INCREASED				
	BLOOD CREATINE	1 (1%)	0 (0%)	0 (0%)	1 (0%)
	PHOSPHOKINASE				
	INCREASED				
	BLOOD GLUCOSE INCREASED	0 (0%)	1 (1%)	1 (1%)	2 (1%)
	BLOOD URINE PRESENT	1 (1%)	0 (0%)	0 (0%)	1 (0%)
	BODY TEMPERATURE	0 (0%)	1 (1%)	0 (0%)	1 (0%)
	INCREASED				

1.) Only treatment emergent events related to lipids are displayed.

2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 1 and this is page value 2: 1

Body System or Organ Class	Dictionary-Derived Term	Placebo (N=86)		Xanomeline Low Dose (N=96)		Xanomeline High Dose (N=72)		Total (N=254)
		n	(%)	n	(%)	n	(%)	
INVESTIGATIONS	CYSTOSCOPY	1	(1%)	0	(0%)	0	(0%)	1 (0%)
	ELECTROCARDIOGRAM ST SEGMENT DEPRESSION	4	(5%)	1	(1%)	0	(0%)	5 (2%)
	ELECTROCARDIOGRAM T WAVE AMPLITUDE DECREASED	1	(1%)	1	(1%)	0	(0%)	2 (1%)
	ELECTROCARDIOGRAM T WAVE INVERSION	2	(2%)	1	(1%)	1	(1%)	4 (2%)
	HEART RATE INCREASED	1	(1%)	0	(0%)	0	(0%)	1 (0%)
	HEART RATE IRREGULAR	1	(1%)	0	(0%)	0	(0%)	1 (0%)
	NASAL MUCOSA BIOPSY	0	(0%)	1	(1%)	0	(0%)	1 (0%)
	NEUTROPHIL COUNT INCREASED	0	(0%)	1	(1%)	0	(0%)	1 (0%)
	URINE ANALYSIS ABNORMAL	0	(0%)	1	(1%)	0	(0%)	1 (0%)
	WEIGHT DECREASED	0	(0%)	1	(1%)	0	(0%)	1 (0%)
	WHITE BLOOD CELL COUNT INCREASED	0	(0%)	1	(1%)	0	(0%)	1 (0%)
	ANY EVENT	6	(7%)	1	(1%)	3	(4%)	10 (4%)
	DECREASED APPETITE	1	(1%)	0	(0%)	1	(1%)	2 (1%)
	DEHYDRATION	1	(1%)	0	(0%)	0	(0%)	1 (0%)
	DIABETES MELLITUS	1	(1%)	0	(0%)	0	(0%)	1 (0%)
	FOOD CRAVING	1	(1%)	1	(1%)	0	(0%)	2 (1%)

- 1.) Only treatment emergent events related to lipids are displayed.
- 2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 1 and this is page value 2: 1

Body System or Organ Class	Dictionary-Derived Term	Placebo		Xanomeline		Total (N=254)	
		(N=86)		Low Dose (N=96)			
		n	(%)	n	(%)		
METABOLISM AND NUTRITION DISORDERS	HYPERCHOLESTEROLAEMIA	0	(0%)	0	(0%)	1 (0%)	
	HYPONATRAEMIA	1	(1%)	0	(0%)	0 (0%)	
	INCREASED APPETITE	1	(1%)	0	(0%)	1 (1%)	
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS	ANY EVENT	5	(6%)	7	(7%)	8 (11%)	
	ARTHRALGIA	1	(1%)	2	(2%)	1 (1%)	
	ARTHRITIS	1	(1%)	0	(0%)	1 (1%)	
	BACK PAIN	1	(1%)	1	(1%)	3 (4%)	
	FLANK PAIN	0	(0%)	0	(0%)	2 (3%)	
	MUSCLE SPASMS	0	(0%)	1	(1%)	1 (1%)	
	MUSCULAR WEAKNESS	0	(0%)	1	(1%)	0 (0%)	
	MYALGIA	0	(0%)	0	(0%)	1 (0%)	
	PAIN IN EXTREMITY	1	(1%)	0	(0%)	0 (0%)	

1.) Only treatment emergent events related to lipids are displayed.

2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 1 and this is page value 2: 1

Body System or Organ Class	Dictionary-Derived Term	Placebo (N=86) n (%)	Xanomeline Low Dose (N=96) n (%)	Xanomeline High Dose (N=72) n (%)	Total (N=254) n (%)
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS	SHOULDER PAIN	1 (1%)	2 (2%)	0 (0%)	3 (1%)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ANY EVENT	0 (0%)	2 (2%)	1 (1%)	3 (1%)
	COLON CANCER	0 (0%)	1 (1%)	0 (0%)	1 (0%)
	MALIGNANT FIBROUS HISTIOCYTOMA	0 (0%)	1 (1%)	0 (0%)	1 (0%)
	PROSTATE CANCER	0 (0%)	0 (0%)	1 (1%)	1 (0%)
NERVOUS SYSTEM DISORDERS	ANY EVENT	12 (14%)	22 (23%)	25 (35%)	59 (23%)
	AMNESIA	0 (0%)	0 (0%)	1 (1%)	1 (0%)
	BALANCE DISORDER	0 (0%)	1 (1%)	0 (0%)	1 (0%)
	BURNING SENSATION	0 (0%)	0 (0%)	2 (3%)	2 (1%)
	COGNITIVE DISORDER	0 (0%)	0 (0%)	1 (1%)	1 (0%)
	COMPLEX PARTIAL SEIZURES	0 (0%)	1 (1%)	0 (0%)	1 (0%)
	COORDINATION ABNORMAL	0 (0%)	1 (1%)	0 (0%)	1 (0%)
	DIZZINESS	2 (2%)	9 (9%)	11 (15%)	22 (9%)
	HEADACHE	7 (8%)	3 (3%)	6 (8%)	16 (6%)
	HEMIANOPIA HOMONYMOUS	0 (0%)	1 (1%)	0 (0%)	1 (0%)

- 1.) Only treatment emergent events related to lipids are displayed.  
 2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 1 and this is page value 2: 1

Body System or Organ Class	Dictionary-Derived Term	Placebo		Xanomeline		Total (N=254)	
		(N=86)		Low Dose (N=96)			
		n	(%)	n	(%)		
NERVOUS SYSTEM DISORDERS	HYPERSOMNIA	0	(0%)	0	(0%)	1 (0%)	
	LETHARGY	0	(0%)	1	(1%)	2 (1%)	
	PARAESTHESIA	0	(0%)	0	(0%)	1 (0%)	
	PARAESTHESIA ORAL	0	(0%)	1	(1%)	1 (0%)	
	PARKINSON'S DISEASE	1	(1%)	0	(0%)	1 (0%)	
	PAROSMIA	0	(0%)	0	(0%)	1 (0%)	
	PARTIAL SEIZURES WITH SECONDARY GENERALISATION	0	(0%)	0	(0%)	1 (0%)	
	PSYCHOMOTOR HYPERACTIVITY	1	(1%)	0	(0%)	1 (0%)	
	SOMNOLENCE	2	(2%)	3	(3%)	6 (2%)	
	STUPOR	0	(0%)	1	(1%)	1 (0%)	
	SYNCOPE	0	(0%)	5	(5%)	7 (3%)	
	SYNCOPE VASOVAGAL	0	(0%)	0	(0%)	1 (0%)	
	TRANSIENT ISCHAEMIC ATTACK	0	(0%)	2	(2%)	3 (1%)	
PSYCHIATRIC DISORDERS	ANY EVENT	10	(12%)	11	(11%)	29 (11%)	
	AGITATION	2	(2%)	3	(3%)	5 (2%)	
	ANXIETY	1	(1%)	3	(3%)	4 (2%)	
	COMPLETED SUICIDE	1	(1%)	0	(0%)	1 (0%)	
	CONFUSIONAL STATE	2	(2%)	3	(3%)	6 (2%)	

1.) Only treatment emergent events related to lipids are displayed.

2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 1 and this is page value 2: 1

Body System or Organ Class	Dictionary-Derived Term	Placebo (N=86)		Xanomeline		Total (N=254) n (%)
		n (%)	n (%)	Low Dose (N=96)	High Dose (N=72)	
PSYCHIATRIC DISORDERS	DELIRIUM	0 (0%)	0 (0%)	1 (1%)	1 (1%)	1 (0%)
	DELUSION	1 (1%)	0 (0%)	1 (1%)	1 (1%)	2 (1%)
	DEPRESSED MOOD	0 (0%)	1 (1%)	1 (1%)	1 (1%)	2 (1%)
	DISORIENTATION	1 (1%)	0 (0%)	0 (0%)	1 (0%)	1 (0%)
	HALLUCINATION	0 (0%)	0 (0%)	1 (1%)	1 (1%)	1 (0%)
	HALLUCINATION, VISUAL	0 (0%)	0 (0%)	1 (1%)	1 (1%)	1 (0%)
	INSOMNIA	2 (2%)	0 (0%)	2 (3%)	4 (2%)	4 (2%)
	IRRITABILITY	1 (1%)	1 (1%)	0 (0%)	2 (1%)	2 (1%)
	LIBIDO DECREASED	0 (0%)	0 (0%)	1 (1%)	1 (1%)	1 (0%)
	LISTLESS	0 (0%)	0 (0%)	1 (1%)	1 (1%)	1 (0%)
	NIGHTMARE	0 (0%)	0 (0%)	1 (1%)	1 (1%)	1 (0%)
	RESTLESSNESS	0 (0%)	1 (1%)	0 (0%)	1 (0%)	1 (0%)
RENAL AND URINARY DISORDERS	ANY EVENT	4 (5%)	4 (4%)	3 (4%)	11 (4%)	11 (4%)
	CALCULUS URETHRAL	0 (0%)	0 (0%)	1 (1%)	1 (0%)	1 (0%)
	DYSURIA	1 (1%)	1 (1%)	0 (0%)	2 (1%)	2 (1%)
	ENURESIS	0 (0%)	1 (1%)	0 (0%)	1 (0%)	1 (0%)
	INCONTINENCE	0 (0%)	1 (1%)	0 (0%)	1 (0%)	1 (0%)
	MICTURITION URGENCY	1 (1%)	1 (1%)	1 (1%)	3 (1%)	3 (1%)
	NEPHROLITHIASIS	1 (1%)	0 (0%)	1 (1%)	2 (1%)	2 (1%)
	POLLAKIURIA	1 (1%)	0 (0%)	0 (0%)	1 (0%)	1 (0%)

- 1.) Only treatment emergent events related to lipids are displayed.  
 2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 1 and this is page value 2: 1

Body System or Organ Class	Dictionary-Derived Term	Placebo (N=86)		Xanomeline Low Dose (N=96)		Xanomeline High Dose (N=72)		Total (N=254)
		n	(%)	n	(%)	n	(%)	
REPRODUCTIVE SYSTEM AND BREAST DISORDERS	ANY EVENT	2	(2%)	0	(0%)	1	(1%)	3 (1%)
	BENIGN PROSTATIC HYPERPLASIA	1	(1%)	0	(0%)	1	(1%)	2 (1%)
	PELVIC PAIN	1	(1%)	0	(0%)	0	(0%)	1 (0%)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	ANY EVENT	10	(12%)	10	(10%)	10	(14%)	30 (12%)
	ALLERGIC GRANULOMATOUS ANGIITIS	0	(0%)	0	(0%)	1	(1%)	1 (0%)
	COUGH	3	(3%)	6	(6%)	5	(7%)	14 (6%)
	DYSPHONIA	0	(0%)	1	(1%)	0	(0%)	1 (0%)
	DYSPNOEA	1	(1%)	1	(1%)	1	(1%)	3 (1%)
	EMPHYSEMA	1	(1%)	0	(0%)	0	(0%)	1 (0%)
	EPISTAXIS	0	(0%)	1	(1%)	2	(3%)	3 (1%)
	HAEMOPTYSIS	1	(1%)	0	(0%)	0	(0%)	1 (0%)

1.) Only treatment emergent events related to lipids are displayed.

2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 1 and this is page value 2: 1

Body System or Organ Class	Dictionary-Derived Term	Placebo (N=86) n (%)	Xanomeline Low Dose (N=96) n (%)	Xanomeline High Dose (N=72) n (%)	Total (N=254) n (%)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	NASAL CONGESTION	3 (3%)	1 (1%)	3 (4%)	7 (3%)
	PHARYNGEAL ERYTHEMA	0 (0%)	0 (0%)	1 (1%)	1 (0%)
	PHARYNGOLARYNGEAL PAIN	0 (0%)	1 (1%)	1 (1%)	2 (1%)
	POSTNASAL DRIP	1 (1%)	0 (0%)	0 (0%)	1 (0%)
	PRODUCTIVE COUGH	0 (0%)	0 (0%)	1 (1%)	1 (0%)
	RALES	1 (1%)	0 (0%)	0 (0%)	1 (0%)
	RESPIRATORY TRACT CONGESTION	0 (0%)	0 (0%)	1 (1%)	1 (0%)
	RHINORRHOEA	0 (0%)	1 (1%)	1 (1%)	2 (1%)
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	ANY EVENT	21 (24%)	42 (44%)	42 (58%)	105 (41%)
	ACTINIC KERATOSIS	0 (0%)	0 (0%)	1 (1%)	1 (0%)
	ALOPECIA	1 (1%)	0 (0%)	0 (0%)	1 (0%)
	BLISTER	0 (0%)	5 (5%)	1 (1%)	6 (2%)
	COLD SWEAT	1 (1%)	0 (0%)	0 (0%)	1 (0%)

- 1.) Only treatment emergent events related to lipids are displayed.
- 2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 1 and this is page value 2: 1

Body System or Organ Class	Dictionary-Derived Term	Placebo (N=86)		Xanomeline Low Dose (N=96)		Xanomeline High Dose (N=72)		Total (N=254)
		n	(%)	n	(%)	n	(%)	
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	DERMATITIS ATOPIC	1	(1%)	0	(0%)	0	(0%)	1 (0%)
	DERMATITIS CONTACT	0	(0%)	1	(1%)	0	(0%)	1 (0%)
	DRUG ERUPTION	1	(1%)	0	(0%)	0	(0%)	1 (0%)
	ERYTHEMA	9	(10%)	15	(16%)	14	(19%)	38 (15%)
	HYPERHIDROSIS	2	(2%)	4	(4%)	8	(11%)	14 (6%)
	PRURITUS	8	(9%)	23	(24%)	26	(36%)	57 (22%)
	PRURITUS GENERALISED	0	(0%)	1	(1%)	1	(1%)	2 (1%)
	RASH	5	(6%)	13	(14%)	11	(15%)	29 (11%)
	RASH ERYTHEMATOUS	0	(0%)	2	(2%)	0	(0%)	2 (1%)
	RASH MACULO-PAPULAR	0	(0%)	0	(0%)	1	(1%)	1 (0%)
	RASH PAPULAR	0	(0%)	0	(0%)	1	(1%)	1 (0%)
	RASH PRURITIC	0	(0%)	1	(1%)	2	(3%)	3 (1%)
	SKIN EXFOLIATION	0	(0%)	1	(1%)	0	(0%)	1 (0%)
	SKIN IRRITATION	3	(3%)	6	(6%)	5	(7%)	14 (6%)
	SKIN ODOUR ABNORMAL	0	(0%)	0	(0%)	1	(1%)	1 (0%)
	SKIN ULCER	1	(1%)	0	(0%)	0	(0%)	1 (0%)
	URTICARIA	0	(0%)	1	(1%)	1	(1%)	2 (1%)
SOCIAL CIRCUMSTANCES	ANY EVENT	0	(0%)	0	(0%)	1	(1%)	1 (0%)
	ALCOHOL USE	0	(0%)	0	(0%)	1	(1%)	1 (0%)
SURGICAL AND MEDICAL PROCEDURES	ANY EVENT	2	(2%)	1	(1%)	2	(3%)	5 (2%)
	ACROCHORDON EXCISION	0	(0%)	0	(0%)	1	(1%)	1 (0%)

- 1.) Only treatment emergent events related to lipids are displayed.
- 2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 1 and this is page value 2: 1

Body System or Organ Class	Dictionary-Derived Term	Placebo (N=86) n (%)	Xanomeline Low Dose (N=96) n (%)	Xanomeline High Dose (N=72) n (%)	Total (N=254) n (%)
SURGICAL AND MEDICAL PROCEDURES	CATARACT OPERATION	1 (1%)	1 (1%)	0 (0%)	2 (1%)
	EYE LASER SURGERY	1 (1%)	0 (0%)	0 (0%)	1 (0%)
	SKIN LESION EXCISION	0 (0%)	0 (0%)	1 (1%)	1 (0%)
VASCULAR DISORDERS	ANY EVENT	3 (3%)	4 (4%)	1 (1%)	8 (3%)
	HOT FLUSH	0 (0%)	1 (1%)	0 (0%)	1 (0%)
	HYPERTENSION	1 (1%)	2 (2%)	0 (0%)	3 (1%)
	HYPOTENSION	2 (2%)	1 (1%)	0 (0%)	3 (1%)
	ORTHOSTATIC HYPOTENSION	1 (1%)	0 (0%)	0 (0%)	1 (0%)
	WOUND HAEMORRHAGE	0 (0%)	0 (0%)	1 (1%)	1 (0%)

- 1.) Only treatment emergent events related to lipids are displayed.  
 2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 1 and this is page value 2: 2

Body System or Organ Class	Dictionary-Derived Term	Placebo		Xanomeline		Total (N=254)	
		(N=86)		Low Dose (N=96)			
		n	(%)	n	(%)		
ANY EVENT	ANY EVENT	69	(80%)	86	(90%)	70 (97%)	225 (89%)
CARDIAC DISORDERS	ANY EVENT	13	(15%)	16	(17%)	15 (21%)	44 (17%)
	ATRIAL FIBRILLATION	1	(1%)	2	(2%)	2 (3%)	5 (2%)
	ATRIAL FLUTTER	0	(0%)	1	(1%)	1 (1%)	2 (1%)
	ATRIAL HYPERTROPHY	1	(1%)	0	(0%)	0 (0%)	1 (0%)
	ATRIOVENTRICULAR BLOCK	1	(1%)	1	(1%)	0 (0%)	2 (1%)
	FIRST DEGREE						
	ATRIOVENTRICULAR BLOCK	2	(2%)	2	(2%)	1 (1%)	5 (2%)
	SECOND DEGREE						
	BRADYCARDIA	1	(1%)	0	(0%)	0 (0%)	1 (0%)
	BUNDLE BRANCH BLOCK	1	(1%)	0	(0%)	0 (0%)	1 (0%)
	LEFT						
	BUNDLE BRANCH BLOCK	1	(1%)	1	(1%)	0 (0%)	2 (1%)
	RIGHT						
	CARDIAC DISORDER	0	(0%)	0	(0%)	1 (1%)	1 (0%)
	CARDIAC FAILURE	1	(1%)	0	(0%)	0 (0%)	1 (0%)
	CONGESTIVE						
	MYOCARDIAL INFARCTION	4	(5%)	2	(2%)	4 (6%)	10 (4%)
	PALPITATIONS	0	(0%)	2	(2%)	0 (0%)	2 (1%)
	SINUS ARRHYTHMIA	1	(1%)	0	(0%)	0 (0%)	1 (0%)
	SINUS BRADYCARDIA	2	(2%)	7	(7%)	8 (11%)	17 (7%)
	SUPRAVENTRICULAR						
	EXTRASYSTOLES	1	(1%)	1	(1%)	1 (1%)	3 (1%)

- 1.) Only treatment emergent events related to lipids are displayed.  
 2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 1 and this is page value 2: 2

Body System or Organ Class	Dictionary-Derived Term	Placebo	Xanomeline	Xanomeline	Total
		(N=86) n (%)	Low Dose (N=96) n (%)	High Dose (N=72) n (%)	(N=254) n (%)
CARDIAC DISORDERS	SUPRAVENTRICULAR TACHYCARDIA	0 (0%)	1 (1%)	0 (0%)	1 (0%)
	TACHYCARDIA	1 (1%)	0 (0%)	0 (0%)	1 (0%)
	VENTRICULAR EXTRASYSTOLES	0 (0%)	2 (2%)	1 (1%)	3 (1%)
	VENTRICULAR HYPERTROPHY	1 (1%)	0 (0%)	0 (0%)	1 (0%)
	WOLFF-PARKINSON-WHITE SYNDROME	0 (0%)	1 (1%)	0 (0%)	1 (0%)
CONGENITAL, FAMILIAL AND GENETIC DISORDERS	ANY EVENT	0 (0%)	1 (1%)	2 (3%)	3 (1%)
	VENTRICULAR SEPTAL DEFECT	0 (0%)	1 (1%)	2 (3%)	3 (1%)
EAR AND LABYRINTH DISORDERS	ANY EVENT	1 (1%)	2 (2%)	1 (1%)	4 (2%)
	CERUMEN IMPACTION	0 (0%)	1 (1%)	0 (0%)	1 (0%)
	EAR PAIN	1 (1%)	0 (0%)	0 (0%)	1 (0%)
	TINNITUS	0 (0%)	1 (1%)	0 (0%)	1 (0%)
	VERTIGO	0 (0%)	1 (1%)	1 (1%)	2 (1%)
EYE DISORDERS	ANY EVENT	4 (5%)	2 (2%)	1 (1%)	7 (3%)
	CONJUNCTIVAL HAEMORRHAGE	0 (0%)	1 (1%)	0 (0%)	1 (0%)

- 1.) Only treatment emergent events related to lipids are displayed.  
 2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 1 and this is page value 2: 2

Body System or Organ Class	Dictionary-Derived Term	Placebo		Xanomeline		Total (N=254)			
		(N=86)		Low Dose (N=96)					
		n	(%)	n	(%)				
EYE DISORDERS	CONJUNCTIVITIS	2	(2%)	0	(0%)	0	(0%)	2	(1%)
	EYE ALLERGY	1	(1%)	0	(0%)	0	(0%)	1	(0%)
	EYE PRURITUS	1	(1%)	0	(0%)	0	(0%)	1	(0%)
	EYE SWELLING	1	(1%)	0	(0%)	0	(0%)	1	(0%)
	GLAUCOMA	1	(1%)	0	(0%)	0	(0%)	1	(0%)
	VISION BLURRED	0	(0%)	1	(1%)	1	(1%)	2	(1%)
GASTROINTESTINAL DISORDERS	ANY EVENT	17	(20%)	16	(17%)	20	(28%)	53	(21%)
	ABDOMINAL DISCOMFORT	0	(0%)	0	(0%)	1	(1%)	1	(0%)
	ABDOMINAL PAIN	1	(1%)	3	(3%)	1	(1%)	5	(2%)
	CONSTIPATION	1	(1%)	0	(0%)	0	(0%)	1	(0%)
	DIARRHOEA	9	(10%)	6	(6%)	3	(4%)	18	(7%)
	DYSPEPSIA	1	(1%)	1	(1%)	1	(1%)	3	(1%)
	DYSPHAGIA	0	(0%)	1	(1%)	0	(0%)	1	(0%)
	FLATULENCE	1	(1%)	0	(0%)	0	(0%)	1	(0%)
	GASTROINTESTINAL HAEMORRHAGE	0	(0%)	0	(0%)	1	(1%)	1	(0%)
	GASTROESOPHAGEAL REFLUX DISEASE	1	(1%)	0	(0%)	0	(0%)	1	(0%)
	GLOSSITIS	1	(1%)	0	(0%)	0	(0%)	1	(0%)
	HIATUS HERNIA	1	(1%)	0	(0%)	0	(0%)	1	(0%)
	NAUSEA	3	(3%)	3	(3%)	6	(8%)	12	(5%)
	RECTAL HAEMORRHAGE	0	(0%)	1	(1%)	0	(0%)	1	(0%)

- 1.) Only treatment emergent events related to lipids are displayed.
- 2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 1 and this is page value 2: 2

Body System or Organ Class	Dictionary-Derived Term	Placebo		Xanomeline		Total (N=254)	
		(N=86)		Low Dose (N=96)			
		n	(%)	n	(%)		
GASTROINTESTINAL DISORDERS	SALIVARY HYPERSECRETION	0	(0%)	0	(0%)	4 (6%)	
	STOMACH DISCOMFORT	0	(0%)	0	(0%)	1 (1%)	
	VOMITING	3	(3%)	4	(4%)	6 (8%)	
						13 (5%)	
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	ANY EVENT	21	(24%)	51	(53%)	36 (50%)	
	APPLICATION SITE BLEEDING	0	(0%)	1	(1%)	0 (0%)	
	APPLICATION SITE DERMATITIS	5	(6%)	9	(9%)	7 (10%)	
	APPLICATION SITE DESQUAMATION	0	(0%)	1	(1%)	0 (0%)	
	APPLICATION SITE DISCHARGE	0	(0%)	0	(0%)	1 (1%)	
	APPLICATION SITE DISCOLOURATION	0	(0%)	1	(1%)	0 (0%)	
	APPLICATION SITE ERYTHEMA	3	(3%)	13	(14%)	14 (19%)	
	APPLICATION SITE INDURATION	1	(1%)	0	(0%)	0 (0%)	
	APPLICATION SITE IRRITATION	3	(3%)	9	(9%)	9 (12%)	
						21 (8%)	

1.) Only treatment emergent events related to lipids are displayed.

2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 1 and this is page value 2: 2

Body System or Organ Class	Dictionary-Derived Term	Placebo (N=86)		Xanomeline Low Dose (N=96)		Xanomeline High Dose (N=72)		Total (N=254)
		n	(%)	n	(%)	n	(%)	
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	APPLICATION SITE PAIN	0	(0%)	0	(0%)	2	(3%)	2 (1%)
	APPLICATION SITE PERSPIRATION	0	(0%)	0	(0%)	2	(3%)	2 (1%)
	APPLICATION SITE PRURITUS	6	(7%)	23	(24%)	21	(29%)	50 (20%)
	APPLICATION SITE REACTION	1	(1%)	0	(0%)	1	(1%)	2 (1%)
	APPLICATION SITE SWELLING	0	(0%)	1	(1%)	2	(3%)	3 (1%)
	APPLICATION SITE URTICARIA	0	(0%)	2	(2%)	1	(1%)	3 (1%)
	APPLICATION SITE VESICLES	1	(1%)	5	(5%)	5	(7%)	11 (4%)
	APPLICATION SITE WARMTH	0	(0%)	1	(1%)	0	(0%)	1 (0%)
	ASTHENIA	1	(1%)	1	(1%)	0	(0%)	2 (1%)
	CHEST DISCOMFORT	0	(0%)	1	(1%)	1	(1%)	2 (1%)
	CHEST PAIN	0	(0%)	0	(0%)	2	(3%)	2 (1%)
	CHILLS	1	(1%)	1	(1%)	1	(1%)	3 (1%)

- 1.) Only treatment emergent events related to lipids are displayed.
- 2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 1 and this is page value 2: 2

Body System or Organ Class	Dictionary-Derived Term	Placebo		Xanomeline		Xanomeline		Total (N=254)	
		(N=86)		Low Dose (N=96)		High Dose (N=72)			
		n	(%)	n	(%)	n	(%)		
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	CYST	0	(0%)	1	(1%)	0	(0%)	1 (0%)	
	FATIGUE	1	(1%)	5	(5%)	5	(7%)	11 (4%)	
	FEELING ABNORMAL	0	(0%)	0	(0%)	1	(1%)	1 (0%)	
	FEELING COLD	0	(0%)	0	(0%)	1	(1%)	1 (0%)	
	INFLAMMATION	0	(0%)	1	(1%)	0	(0%)	1 (0%)	
	MALAISE	0	(0%)	1	(1%)	2	(3%)	3 (1%)	
	OEDEMA	0	(0%)	2	(2%)	0	(0%)	2 (1%)	
	OEDEMA PERIPHERAL	2	(2%)	1	(1%)	2	(3%)	5 (2%)	
	PAIN	0	(0%)	1	(1%)	1	(1%)	2 (1%)	
	PYREXIA	2	(2%)	1	(1%)	0	(0%)	3 (1%)	
	SECRETION DISCHARGE	0	(0%)	1	(1%)	0	(0%)	1 (0%)	

1.) Only treatment emergent events related to lipids are displayed.

2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 1 and this is page value 2: 2

Body System or Organ Class	Dictionary-Derived Term	Placebo		Xanomeline		Total (N=254)	
		(N=86)		Low Dose (N=96)			
		n	(%)	n	(%)		
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	SUDDEN DEATH	0	(0%)	1	(1%)	0 (0%)	
	SWELLING	0	(0%)	1	(1%)	0 (0%)	
	ULCER	0	(0%)	1	(1%)	0 (0%)	
HEPATOBILIARY DISORDERS	ANY EVENT	1	(1%)	0	(0%)	0 (0%)	
	HYPERBILIRUBINAEMIA	1	(1%)	0	(0%)	0 (0%)	
IMMUNE SYSTEM DISORDERS	ANY EVENT	0	(0%)	1	(1%)	1 (0%)	
	HYPERSENSITIVITY	0	(0%)	1	(1%)	0 (0%)	
	SEASONAL ALLERGY	0	(0%)	0	(0%)	1 (0%)	
INFECTIONS AND INFESTATIONS	ANY EVENT	16	(19%)	10	(10%)	13 (18%)	
	BRONCHITIS	1	(1%)	0	(0%)	0 (0%)	
	CELLULITIS	0	(0%)	1	(1%)	0 (0%)	
	CERVICITIS	1	(1%)	0	(0%)	0 (0%)	
	CYSTITIS	1	(1%)	0	(0%)	1 (1%)	
	EAR INFECTION	2	(2%)	0	(0%)	0 (0%)	
	GASTROENTERITIS VIRAL	1	(1%)	0	(0%)	0 (0%)	
	HORDEOLUM	0	(0%)	0	(0%)	1 (1%)	
	INFLUENZA	1	(1%)	1	(1%)	1 (1%)	

- 1.) Only treatment emergent events related to lipids are displayed.
- 2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 1 and this is page value 2: 2

Body System or Organ Class	Dictionary-Derived Term	Placebo		Xanomeline		Total (N=254)	
		(N=86)		Low Dose (N=96)			
		n	(%)	n	(%)		
INFECTIONS AND INFESTATIONS	LOCALISED INFECTION	1	(1%)	1	(1%)	0 (0%)	
	LOWER RESPIRATORY TRACT INFECTION	0	(0%)	0	(0%)	1 (1%)	
	NASOPHARYNGITIS	2	(2%)	4	(4%)	6 (8%)	
	ONYCHOMYCOSIS	0	(0%)	1	(1%)	0 (0%)	
	PNEUMONIA	0	(0%)	1	(1%)	0 (0%)	
	RHINITIS	0	(0%)	0	(0%)	1 (1%)	
	UPPER RESPIRATORY TRACT INFECTION	6	(7%)	1	(1%)	3 (4%)	
	URINARY TRACT INFECTION	2	(2%)	0	(0%)	1 (1%)	
	VAGINAL MYCOSIS	1	(1%)	0	(0%)	1 (0%)	
	VIRAL INFECTION	0	(0%)	1	(1%)	0 (0%)	
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	ANY EVENT	4	(5%)	5	(5%)	5 (7%)	
	CONTUSION	1	(1%)	1	(1%)	2 (3%)	
	EXCORIATION	2	(2%)	1	(1%)	1 (1%)	
	FACIAL BONES FRACTURE	0	(0%)	0	(0%)	1 (0%)	
	FALL	1	(1%)	2	(2%)	1 (1%)	

1.) Only treatment emergent events related to lipids are displayed.

2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 1 and this is page value 2: 2

Body System or Organ Class	Dictionary-Derived Term	Placebo		Xanomeline		Total (N=254)	
		(N=86)		Low Dose (N=96)			
		n	(%)	n	(%)		
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	HIP FRACTURE	1	(1%)	0	(0%)	2 (3%)	
	JOINT DISLOCATION	0	(0%)	1	(1%)	0 (0%)	
	SKIN LACERATION	1	(1%)	2	(2%)	0 (0%)	
	WOUND	0	(0%)	1	(1%)	0 (0%)	
INVESTIGATIONS	ANY EVENT	10	(12%)	8	(8%)	5 (7%)	
	BIOPSY	0	(0%)	0	(0%)	1 (1%)	
	BIOPSY PROSTATE	0	(0%)	0	(0%)	1 (1%)	
	BLOOD ALKALINE	1	(1%)	0	(0%)	0 (0%)	
	PHOSPHATASE INCREASED						
	BLOOD CHOLESTEROL	0	(0%)	0	(0%)	1 (1%)	
	INCREASED						
	BLOOD CREATINE	1	(1%)	0	(0%)	0 (0%)	
	PHOSPHOKINASE						
	INCREASED						
	BLOOD GLUCOSE INCREASED	0	(0%)	1	(1%)	1 (1%)	
	BLOOD URINE PRESENT	1	(1%)	0	(0%)	0 (0%)	
	BODY TEMPERATURE	0	(0%)	1	(1%)	0 (0%)	
	INCREASED						

1.) Only treatment emergent events related to lipids are displayed.

2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 1 and this is page value 2: 2

Body System or Organ Class	Dictionary-Derived Term	Placebo		Xanomeline		Total (N=254)	
		(N=86)		Low Dose (N=96)			
		n	(%)	n	(%)		
INVESTIGATIONS	CYSTOSCOPY	1	(1%)	0	(0%)	0 (0%)	
	ELECTROCARDIOGRAM ST SEGMENT DEPRESSION	4	(5%)	1	(1%)	0 (0%)	
	ELECTROCARDIOGRAM T WAVE AMPLITUDE DECREASED	1	(1%)	1	(1%)	0 (0%)	
	ELECTROCARDIOGRAM T WAVE INVERSION	2	(2%)	1	(1%)	1 (1%)	
	HEART RATE INCREASED	1	(1%)	0	(0%)	1 (0%)	
	HEART RATE IRREGULAR	1	(1%)	0	(0%)	0 (0%)	
	NASAL MUCOSA BIOPSY	0	(0%)	1	(1%)	1 (0%)	
	NEUTROPHIL COUNT INCREASED	0	(0%)	1	(1%)	0 (0%)	
	URINE ANALYSIS ABNORMAL	0	(0%)	1	(1%)	1 (0%)	
	WEIGHT DECREASED	0	(0%)	1	(1%)	0 (0%)	
	WHITE BLOOD CELL COUNT INCREASED	0	(0%)	1	(1%)	1 (0%)	
METABOLISM AND NUTRITION DISORDERS	ANY EVENT	6	(7%)	1	(1%)	3 (4%)	
	DECREASED APPETITE	1	(1%)	0	(0%)	1 (1%)	
	DEHYDRATION	1	(1%)	0	(0%)	0 (0%)	
	DIABETES MELLITUS	1	(1%)	0	(0%)	1 (0%)	
	FOOD CRAVING	1	(1%)	1	(1%)	0 (0%)	

- 1.) Only treatment emergent events related to lipids are displayed.
- 2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 1 and this is page value 2: 2

Body System or Organ Class	Dictionary-Derived Term	Placebo		Xanomeline		Total (N=254)	
		(N=86)		Low Dose (N=96)			
		n	(%)	n	(%)		
METABOLISM AND NUTRITION DISORDERS	HYPERCHOLESTEROLAEMIA	0	(0%)	0	(0%)	1 (0%)	
	HYPONATRAEMIA	1	(1%)	0	(0%)	0 (0%)	
	INCREASED APPETITE	1	(1%)	0	(0%)	1 (1%)	
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS	ANY EVENT	5	(6%)	7	(7%)	8 (11%)	
	ARTHRALGIA	1	(1%)	2	(2%)	1 (1%)	
	ARTHRITIS	1	(1%)	0	(0%)	1 (1%)	
	BACK PAIN	1	(1%)	1	(1%)	3 (4%)	
	FLANK PAIN	0	(0%)	0	(0%)	2 (3%)	
	MUSCLE SPASMS	0	(0%)	1	(1%)	1 (1%)	
	MUSCULAR WEAKNESS	0	(0%)	1	(1%)	0 (0%)	
	MYALGIA	0	(0%)	0	(0%)	1 (0%)	
	PAIN IN EXTREMITY	1	(1%)	0	(0%)	0 (0%)	

1.) Only treatment emergent events related to lipids are displayed.

2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 1 and this is page value 2: 2

Body System or Organ Class	Dictionary-Derived Term	Placebo (N=86) n (%)	Xanomeline Low Dose (N=96) n (%)	Xanomeline High Dose (N=72) n (%)	Total (N=254) n (%)
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS	SHOULDER PAIN	1 (1%)	2 (2%)	0 (0%)	3 (1%)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ANY EVENT	0 (0%)	2 (2%)	1 (1%)	3 (1%)
	COLON CANCER	0 (0%)	1 (1%)	0 (0%)	1 (0%)
	MALIGNANT FIBROUS HISTIOCYTOMA	0 (0%)	1 (1%)	0 (0%)	1 (0%)
	PROSTATE CANCER	0 (0%)	0 (0%)	1 (1%)	1 (0%)
NERVOUS SYSTEM DISORDERS	ANY EVENT	12 (14%)	22 (23%)	25 (35%)	59 (23%)
	AMNESIA	0 (0%)	0 (0%)	1 (1%)	1 (0%)
	BALANCE DISORDER	0 (0%)	1 (1%)	0 (0%)	1 (0%)
	BURNING SENSATION	0 (0%)	0 (0%)	2 (3%)	2 (1%)
	COGNITIVE DISORDER	0 (0%)	0 (0%)	1 (1%)	1 (0%)
	COMPLEX PARTIAL SEIZURES	0 (0%)	1 (1%)	0 (0%)	1 (0%)
	COORDINATION ABNORMAL	0 (0%)	1 (1%)	0 (0%)	1 (0%)
	DIZZINESS	2 (2%)	9 (9%)	11 (15%)	22 (9%)
	HEADACHE	7 (8%)	3 (3%)	6 (8%)	16 (6%)
	HEMIANOPIA HOMONYMOUS	0 (0%)	1 (1%)	0 (0%)	1 (0%)

- 1.) Only treatment emergent events related to lipids are displayed.  
 2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 1 and this is page value 2: 2

Body System or Organ Class	Dictionary-Derived Term	Placebo		Xanomeline		Total (N=254)	
		(N=86)		Low Dose (N=96)			
		n	(%)	n	(%)		
NERVOUS SYSTEM DISORDERS	HYPERSOMNIA	0	(0%)	0	(0%)	1 (0%)	
	LETHARGY	0	(0%)	1	(1%)	2 (1%)	
	PARAESTHESIA	0	(0%)	0	(0%)	1 (0%)	
	PARAESTHESIA ORAL	0	(0%)	1	(1%)	1 (0%)	
	PARKINSON'S DISEASE	1	(1%)	0	(0%)	1 (0%)	
	PAROSMIA	0	(0%)	0	(0%)	1 (0%)	
	PARTIAL SEIZURES WITH SECONDARY GENERALISATION	0	(0%)	0	(0%)	1 (0%)	
	PSYCHOMOTOR HYPERACTIVITY	1	(1%)	0	(0%)	1 (0%)	
	SOMNOLENCE	2	(2%)	3	(3%)	6 (2%)	
	STUPOR	0	(0%)	1	(1%)	1 (0%)	
	SYNCOPE	0	(0%)	5	(5%)	7 (3%)	
	SYNCOPE VASOVAGAL	0	(0%)	0	(0%)	1 (0%)	
	TRANSIENT ISCHAEMIC ATTACK	0	(0%)	2	(2%)	3 (1%)	
PSYCHIATRIC DISORDERS	ANY EVENT	10	(12%)	11	(11%)	29 (11%)	
	AGITATION	2	(2%)	3	(3%)	5 (2%)	
	ANXIETY	1	(1%)	3	(3%)	4 (2%)	
	COMPLETED SUICIDE	1	(1%)	0	(0%)	1 (0%)	
	CONFUSIONAL STATE	2	(2%)	3	(3%)	6 (2%)	

1.) Only treatment emergent events related to lipids are displayed.

2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 1 and this is page value 2: 2

Body System or Organ Class	Dictionary-Derived Term	Placebo (N=86)		Xanomeline		Total (N=254)
		n	(%)	n	(%)	
PSYCHIATRIC DISORDERS	DELIRIUM	0	(0%)	0	(0%)	1 (0%)
	DELUSION	1	(1%)	0	(0%)	1 (1%)
	DEPRESSED MOOD	0	(0%)	1	(1%)	1 (1%)
	DISORIENTATION	1	(1%)	0	(0%)	1 (0%)
	HALLUCINATION	0	(0%)	0	(0%)	1 (0%)
	HALLUCINATION, VISUAL	0	(0%)	0	(0%)	1 (0%)
	INSOMNIA	2	(2%)	0	(0%)	4 (2%)
	IRRITABILITY	1	(1%)	1	(1%)	2 (1%)
	LIBIDO DECREASED	0	(0%)	0	(0%)	1 (0%)
	LISTLESS	0	(0%)	0	(0%)	1 (0%)
	NIGHTMARE	0	(0%)	0	(0%)	1 (0%)
	RESTLESSNESS	0	(0%)	1	(1%)	1 (0%)
RENAL AND URINARY DISORDERS	ANY EVENT	4	(5%)	4	(4%)	11 (4%)
	CALCULUS URETHRAL	0	(0%)	0	(0%)	1 (1%)
	DYSURIA	1	(1%)	1	(1%)	2 (1%)
	ENURESIS	0	(0%)	1	(1%)	1 (0%)
	INCONTINENCE	0	(0%)	1	(1%)	1 (0%)
	MICTURITION URGENCY	1	(1%)	1	(1%)	3 (1%)
	NEPHROLITHIASIS	1	(1%)	0	(0%)	2 (1%)
	POLLAKIURIA	1	(1%)	0	(0%)	1 (0%)

- 1.) Only treatment emergent events related to lipids are displayed.  
 2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 1 and this is page value 2: 2

Body System or Organ Class	Dictionary-Derived Term	Placebo (N=86)		Xanomeline Low Dose (N=96)		Xanomeline High Dose (N=72)		Total (N=254)
		n	(%)	n	(%)	n	(%)	
REPRODUCTIVE SYSTEM AND BREAST DISORDERS	ANY EVENT	2	(2%)	0	(0%)	1	(1%)	3 (1%)
	BENIGN PROSTATIC HYPERPLASIA	1	(1%)	0	(0%)	1	(1%)	2 (1%)
	PELVIC PAIN	1	(1%)	0	(0%)	0	(0%)	1 (0%)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	ANY EVENT	10	(12%)	10	(10%)	10	(14%)	30 (12%)
	ALLERGIC GRANULOMATOUS ANGIITIS	0	(0%)	0	(0%)	1	(1%)	1 (0%)
	COUGH	3	(3%)	6	(6%)	5	(7%)	14 (6%)
	DYSPHONIA	0	(0%)	1	(1%)	0	(0%)	1 (0%)
	DYSPNOEA	1	(1%)	1	(1%)	1	(1%)	3 (1%)
	EMPHYSEMA	1	(1%)	0	(0%)	0	(0%)	1 (0%)
	EPISTAXIS	0	(0%)	1	(1%)	2	(3%)	3 (1%)
	HAEMOPTYSIS	1	(1%)	0	(0%)	0	(0%)	1 (0%)

1.) Only treatment emergent events related to lipids are displayed.

2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 1 and this is page value 2: 2

Body System or Organ Class	Dictionary-Derived Term	Placebo	Xanomeline Low Dose	Xanomeline High Dose	Total
		(N=86) n (%)	(N=96) n (%)	(N=72) n (%)	(N=254) n (%)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	NASAL CONGESTION	3 (3%)	1 (1%)	3 (4%)	7 (3%)
	PHARYNGEAL ERYTHEMA	0 (0%)	0 (0%)	1 (1%)	1 (0%)
	PHARYNGOLARYNGEAL PAIN	0 (0%)	1 (1%)	1 (1%)	2 (1%)
	POSTNASAL DRIP	1 (1%)	0 (0%)	0 (0%)	1 (0%)
	PRODUCTIVE COUGH	0 (0%)	0 (0%)	1 (1%)	1 (0%)
	RALES	1 (1%)	0 (0%)	0 (0%)	1 (0%)
	RESPIRATORY TRACT CONGESTION	0 (0%)	0 (0%)	1 (1%)	1 (0%)
	RHINORRHOEA	0 (0%)	1 (1%)	1 (1%)	2 (1%)
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	ANY EVENT	21 (24%)	42 (44%)	42 (58%)	105 (41%)
	ACTINIC KERATOSIS	0 (0%)	0 (0%)	1 (1%)	1 (0%)
	ALOPECIA	1 (1%)	0 (0%)	0 (0%)	1 (0%)
	BLISTER	0 (0%)	5 (5%)	1 (1%)	6 (2%)
	COLD SWEAT	1 (1%)	0 (0%)	0 (0%)	1 (0%)

1.) Only treatment emergent events related to lipids are displayed.

2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 1 and this is page value 2: 2

Body System or Organ Class	Dictionary-Derived Term	Placebo (N=86)		Xanomeline Low Dose (N=96)		Xanomeline High Dose (N=72)		Total (N=254)
		n	(%)	n	(%)	n	(%)	
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	DERMATITIS ATOPIC	1	(1%)	0	(0%)	0	(0%)	1 (0%)
	DERMATITIS CONTACT	0	(0%)	1	(1%)	0	(0%)	1 (0%)
	DRUG ERUPTION	1	(1%)	0	(0%)	0	(0%)	1 (0%)
	ERYTHEMA	9	(10%)	15	(16%)	14	(19%)	38 (15%)
	HYPERHIDROSIS	2	(2%)	4	(4%)	8	(11%)	14 (6%)
	PRURITUS	8	(9%)	23	(24%)	26	(36%)	57 (22%)
	PRURITUS GENERALISED	0	(0%)	1	(1%)	1	(1%)	2 (1%)
	RASH	5	(6%)	13	(14%)	11	(15%)	29 (11%)
	RASH ERYTHEMATOUS	0	(0%)	2	(2%)	0	(0%)	2 (1%)
	RASH MACULO-PAPULAR	0	(0%)	0	(0%)	1	(1%)	1 (0%)
	RASH PAPULAR	0	(0%)	0	(0%)	1	(1%)	1 (0%)
	RASH PRURITIC	0	(0%)	1	(1%)	2	(3%)	3 (1%)
	SKIN EXFOLIATION	0	(0%)	1	(1%)	0	(0%)	1 (0%)
	SKIN IRRITATION	3	(3%)	6	(6%)	5	(7%)	14 (6%)
	SKIN ODOUR ABNORMAL	0	(0%)	0	(0%)	1	(1%)	1 (0%)
	SKIN ULCER	1	(1%)	0	(0%)	0	(0%)	1 (0%)
	URTICARIA	0	(0%)	1	(1%)	1	(1%)	2 (1%)
SOCIAL CIRCUMSTANCES	ANY EVENT	0	(0%)	0	(0%)	1	(1%)	1 (0%)
	ALCOHOL USE	0	(0%)	0	(0%)	1	(1%)	1 (0%)
SURGICAL AND MEDICAL PROCEDURES	ANY EVENT	2	(2%)	1	(1%)	2	(3%)	5 (2%)
	ACROCHORDON EXCISION	0	(0%)	0	(0%)	1	(1%)	1 (0%)

- 1.) Only treatment emergent events related to lipids are displayed.
- 2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 1 and this is page value 2: 2

Body System or Organ Class	Dictionary-Derived Term	Placebo		Xanomeline		Total (N=254)
		n	(%)	n	(%)	
SURGICAL AND MEDICAL PROCEDURES	CATARACT OPERATION	1	(1%)	1	(1%)	0 (0%)
	EYE LASER SURGERY	1	(1%)	0	(0%)	0 (0%)
	SKIN LESION EXCISION	0	(0%)	0	(0%)	1 (1%)
VASCULAR DISORDERS	ANY EVENT	3	(3%)	4	(4%)	1 (1%)
	HOT FLUSH	0	(0%)	1	(1%)	0 (0%)
	HYPERTENSION	1	(1%)	2	(2%)	0 (0%)
	HYPOTENSION	2	(2%)	1	(1%)	0 (0%)
	ORTHOSTATIC HYPOTENSION	1	(1%)	0	(0%)	0 (0%)
	WOUND HAEMORRHAGE	0	(0%)	0	(0%)	1 (1%)

- 1.) Only treatment emergent events related to lipids are displayed.  
 2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 2 and this is page value 2: 3

Body System or Organ Class	Dictionary-Derived Term	Placebo		Xanomeline		Total (N=254)	
		(N=86)		Low Dose (N=96)			
		n	(%)	n	(%)		
ANY EVENT	ANY EVENT	69	(80%)	86	(90%)	70 (97%)	225 (89%)
CARDIAC DISORDERS	ANY EVENT	13	(15%)	16	(17%)	15 (21%)	44 (17%)
	ATRIAL FIBRILLATION	1	(1%)	2	(2%)	2 (3%)	5 (2%)
	ATRIAL FLUTTER	0	(0%)	1	(1%)	1 (1%)	2 (1%)
	ATRIAL HYPERTROPHY	1	(1%)	0	(0%)	0 (0%)	1 (0%)
	ATRIOVENTRICULAR BLOCK	1	(1%)	1	(1%)	0 (0%)	2 (1%)
	FIRST DEGREE						
	ATRIOVENTRICULAR BLOCK	2	(2%)	2	(2%)	1 (1%)	5 (2%)
	SECOND DEGREE						
	BRADYCARDIA	1	(1%)	0	(0%)	0 (0%)	1 (0%)
	BUNDLE BRANCH BLOCK	1	(1%)	0	(0%)	0 (0%)	1 (0%)
	LEFT						
	BUNDLE BRANCH BLOCK	1	(1%)	1	(1%)	0 (0%)	2 (1%)
	RIGHT						
	CARDIAC DISORDER	0	(0%)	0	(0%)	1 (1%)	1 (0%)
	CARDIAC FAILURE	1	(1%)	0	(0%)	0 (0%)	1 (0%)
	CONGESTIVE						
	MYOCARDIAL INFARCTION	4	(5%)	2	(2%)	4 (6%)	10 (4%)
	PALPITATIONS	0	(0%)	2	(2%)	0 (0%)	2 (1%)
	SINUS ARRHYTHMIA	1	(1%)	0	(0%)	0 (0%)	1 (0%)
	SINUS BRADYCARDIA	2	(2%)	7	(7%)	8 (11%)	17 (7%)
	SUPRAVENTRICULAR						
	EXTRASYSTOLES	1	(1%)	1	(1%)	1 (1%)	3 (1%)

- 1.) Only treatment emergent events related to lipids are displayed.  
 2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 2 and this is page value 2: 3

Body System or Organ Class	Dictionary-Derived Term	Placebo	Xanomeline	Xanomeline	Total
		(N=86) n (%)	Low Dose (N=96) n (%)	High Dose (N=72) n (%)	(N=254) n (%)
CARDIAC DISORDERS	SUPRAVENTRICULAR TACHYCARDIA	0 (0%)	1 (1%)	0 (0%)	1 (0%)
	TACHYCARDIA	1 (1%)	0 (0%)	0 (0%)	1 (0%)
	VENTRICULAR EXTRASYSTOLES	0 (0%)	2 (2%)	1 (1%)	3 (1%)
	VENTRICULAR HYPERTROPHY	1 (1%)	0 (0%)	0 (0%)	1 (0%)
	WOLFF-PARKINSON-WHITE SYNDROME	0 (0%)	1 (1%)	0 (0%)	1 (0%)
CONGENITAL, FAMILIAL AND GENETIC DISORDERS	ANY EVENT	0 (0%)	1 (1%)	2 (3%)	3 (1%)
	VENTRICULAR SEPTAL DEFECT	0 (0%)	1 (1%)	2 (3%)	3 (1%)
EAR AND LABYRINTH DISORDERS	ANY EVENT	1 (1%)	2 (2%)	1 (1%)	4 (2%)
	CERUMEN IMPACTION	0 (0%)	1 (1%)	0 (0%)	1 (0%)
	EAR PAIN	1 (1%)	0 (0%)	0 (0%)	1 (0%)
	TINNITUS	0 (0%)	1 (1%)	0 (0%)	1 (0%)
	VERTIGO	0 (0%)	1 (1%)	1 (1%)	2 (1%)
EYE DISORDERS	ANY EVENT	4 (5%)	2 (2%)	1 (1%)	7 (3%)
	CONJUNCTIVAL HAEMORRHAGE	0 (0%)	1 (1%)	0 (0%)	1 (0%)

1.) Only treatment emergent events related to lipids are displayed.

2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 2 and this is page value 2: 3

Body System or Organ Class	Dictionary-Derived Term	Placebo		Xanomeline		Total (N=254)			
		(N=86)		Low Dose (N=96)					
		n	(%)	n	(%)				
EYE DISORDERS	CONJUNCTIVITIS	2	(2%)	0	(0%)	0	(0%)	2	(1%)
	EYE ALLERGY	1	(1%)	0	(0%)	0	(0%)	1	(0%)
	EYE PRURITUS	1	(1%)	0	(0%)	0	(0%)	1	(0%)
	EYE SWELLING	1	(1%)	0	(0%)	0	(0%)	1	(0%)
	GLAUCOMA	1	(1%)	0	(0%)	0	(0%)	1	(0%)
	VISION BLURRED	0	(0%)	1	(1%)	1	(1%)	2	(1%)
GASTROINTESTINAL DISORDERS	ANY EVENT	17	(20%)	16	(17%)	20	(28%)	53	(21%)
	ABDOMINAL DISCOMFORT	0	(0%)	0	(0%)	1	(1%)	1	(0%)
	ABDOMINAL PAIN	1	(1%)	3	(3%)	1	(1%)	5	(2%)
	CONSTIPATION	1	(1%)	0	(0%)	0	(0%)	1	(0%)
	DIARRHOEA	9	(10%)	6	(6%)	3	(4%)	18	(7%)
	DYSPEPSIA	1	(1%)	1	(1%)	1	(1%)	3	(1%)
	DYSPHAGIA	0	(0%)	1	(1%)	0	(0%)	1	(0%)
	FLATULENCE	1	(1%)	0	(0%)	0	(0%)	1	(0%)
	GASTROINTESTINAL HAEMORRHAGE	0	(0%)	0	(0%)	1	(1%)	1	(0%)
	GASTROESOPHAGEAL REFLUX DISEASE	1	(1%)	0	(0%)	0	(0%)	1	(0%)
	GLOSSITIS	1	(1%)	0	(0%)	0	(0%)	1	(0%)
	HIATUS HERNIA	1	(1%)	0	(0%)	0	(0%)	1	(0%)
	NAUSEA	3	(3%)	3	(3%)	6	(8%)	12	(5%)
	RECTAL HAEMORRHAGE	0	(0%)	1	(1%)	0	(0%)	1	(0%)

- 1.) Only treatment emergent events related to lipids are displayed.
- 2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 2 and this is page value 2: 3

Body System or Organ Class	Dictionary-Derived Term	Placebo		Xanomeline		Total (N=254)	
		(N=86)		Low Dose (N=96)			
		n	(%)	n	(%)		
GASTROINTESTINAL DISORDERS	SALIVARY HYPERSECRETION	0	(0%)	0	(0%)	4 (6%)	
	STOMACH DISCOMFORT	0	(0%)	0	(0%)	1 (1%)	
	VOMITING	3	(3%)	4	(4%)	6 (8%)	
						13 (5%)	
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	ANY EVENT	21	(24%)	51	(53%)	36 (50%)	
	APPLICATION SITE BLEEDING	0	(0%)	1	(1%)	0 (0%)	
	APPLICATION SITE DERMATITIS	5	(6%)	9	(9%)	7 (10%)	
	APPLICATION SITE DESQUAMATION	0	(0%)	1	(1%)	0 (0%)	
	APPLICATION SITE DISCHARGE	0	(0%)	0	(0%)	1 (1%)	
	APPLICATION SITE DISCOLOURATION	0	(0%)	1	(1%)	0 (0%)	
	APPLICATION SITE ERYTHEMA	3	(3%)	13	(14%)	14 (19%)	
	APPLICATION SITE INDURATION	1	(1%)	0	(0%)	0 (0%)	
	APPLICATION SITE IRRITATION	3	(3%)	9	(9%)	9 (12%)	
						21 (8%)	

1.) Only treatment emergent events related to lipids are displayed.

2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 2 and this is page value 2: 3

Body System or Organ Class	Dictionary-Derived Term	Placebo (N=86)		Xanomeline Low Dose (N=96)		Xanomeline High Dose (N=72)		Total (N=254)
		n	(%)	n	(%)	n	(%)	
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	APPLICATION SITE PAIN	0	(0%)	0	(0%)	2	(3%)	2 (1%)
	APPLICATION SITE PERSPIRATION	0	(0%)	0	(0%)	2	(3%)	2 (1%)
	APPLICATION SITE PRURITUS	6	(7%)	23	(24%)	21	(29%)	50 (20%)
	APPLICATION SITE REACTION	1	(1%)	0	(0%)	1	(1%)	2 (1%)
	APPLICATION SITE SWELLING	0	(0%)	1	(1%)	2	(3%)	3 (1%)
	APPLICATION SITE URTICARIA	0	(0%)	2	(2%)	1	(1%)	3 (1%)
	APPLICATION SITE VESICLES	1	(1%)	5	(5%)	5	(7%)	11 (4%)
	APPLICATION SITE WARMTH	0	(0%)	1	(1%)	0	(0%)	1 (0%)
	ASTHENIA	1	(1%)	1	(1%)	0	(0%)	2 (1%)
	CHEST DISCOMFORT	0	(0%)	1	(1%)	1	(1%)	2 (1%)
	CHEST PAIN	0	(0%)	0	(0%)	2	(3%)	2 (1%)
	CHILLS	1	(1%)	1	(1%)	1	(1%)	3 (1%)

- 1.) Only treatment emergent events related to lipids are displayed.
- 2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 2 and this is page value 2: 3

Body System or Organ Class	Dictionary-Derived Term	Placebo		Xanomeline		Xanomeline		Total (N=254)	
		(N=86)		Low Dose (N=96)		High Dose (N=72)			
		n	(%)	n	(%)	n	(%)		
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	CYST	0	(0%)	1	(1%)	0	(0%)	1 (0%)	
	FATIGUE	1	(1%)	5	(5%)	5	(7%)	11 (4%)	
	FEELING ABNORMAL	0	(0%)	0	(0%)	1	(1%)	1 (0%)	
	FEELING COLD	0	(0%)	0	(0%)	1	(1%)	1 (0%)	
	INFLAMMATION	0	(0%)	1	(1%)	0	(0%)	1 (0%)	
	MALAISE	0	(0%)	1	(1%)	2	(3%)	3 (1%)	
	OEDEMA	0	(0%)	2	(2%)	0	(0%)	2 (1%)	
	OEDEMA PERIPHERAL	2	(2%)	1	(1%)	2	(3%)	5 (2%)	
	PAIN	0	(0%)	1	(1%)	1	(1%)	2 (1%)	
	PYREXIA	2	(2%)	1	(1%)	0	(0%)	3 (1%)	
	SECRETION DISCHARGE	0	(0%)	1	(1%)	0	(0%)	1 (0%)	

1.) Only treatment emergent events related to lipids are displayed.

2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 2 and this is page value 2: 3

Body System or Organ Class	Dictionary-Derived Term	Placebo		Xanomeline		Total (N=254)	
		(N=86)		Low Dose (N=96)			
		n	(%)	n	(%)		
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	SUDDEN DEATH	0	(0%)	1	(1%)	0 (0%)	
	SWELLING	0	(0%)	1	(1%)	0 (0%)	
	ULCER	0	(0%)	1	(1%)	0 (0%)	
HEPATOBILIARY DISORDERS	ANY EVENT	1	(1%)	0	(0%)	0 (0%)	
	HYPERBILIRUBINAEMIA	1	(1%)	0	(0%)	0 (0%)	
IMMUNE SYSTEM DISORDERS	ANY EVENT	0	(0%)	1	(1%)	1 (0%)	
	HYPERSENSITIVITY	0	(0%)	1	(1%)	0 (0%)	
	SEASONAL ALLERGY	0	(0%)	0	(0%)	1 (0%)	
INFECTIONS AND INFESTATIONS	ANY EVENT	16	(19%)	10	(10%)	13 (18%)	
	BRONCHITIS	1	(1%)	0	(0%)	0 (0%)	
	CELLULITIS	0	(0%)	1	(1%)	0 (0%)	
	CERVICITIS	1	(1%)	0	(0%)	0 (0%)	
	CYSTITIS	1	(1%)	0	(0%)	1 (1%)	
	EAR INFECTION	2	(2%)	0	(0%)	0 (0%)	
	GASTROENTERITIS VIRAL	1	(1%)	0	(0%)	0 (0%)	
	HORDEOLUM	0	(0%)	0	(0%)	1 (1%)	
	INFLUENZA	1	(1%)	1	(1%)	1 (1%)	

- 1.) Only treatment emergent events related to lipids are displayed.
- 2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 2 and this is page value 2: 3

Body System or Organ Class	Dictionary-Derived Term	Placebo	Xanomeline Low Dose	Xanomeline High Dose	Total
		(N=86) n (%)	(N=96) n (%)	(N=72) n (%)	(N=254) n (%)
INFECTIONS AND INFESTATIONS	LOCALISED INFECTION	1 (1%)	1 (1%)	0 (0%)	2 (1%)
	LOWER RESPIRATORY TRACT INFECTION	0 (0%)	0 (0%)	1 (1%)	1 (0%)
	NASOPHARYNGITIS	2 (2%)	4 (4%)	6 (8%)	12 (5%)
	ONYCHOMYCOSIS	0 (0%)	1 (1%)	0 (0%)	1 (0%)
	PNEUMONIA	0 (0%)	1 (1%)	0 (0%)	1 (0%)
	RHINITIS	0 (0%)	0 (0%)	1 (1%)	1 (0%)
	UPPER RESPIRATORY TRACT INFECTION	6 (7%)	1 (1%)	3 (4%)	10 (4%)
	URINARY TRACT INFECTION	2 (2%)	0 (0%)	1 (1%)	3 (1%)
	VAGINAL MYCOSIS	1 (1%)	0 (0%)	0 (0%)	1 (0%)
	VIRAL INFECTION	0 (0%)	1 (1%)	0 (0%)	1 (0%)
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	ANY EVENT	4 (5%)	5 (5%)	5 (7%)	14 (6%)
	CONTUSION	1 (1%)	1 (1%)	2 (3%)	4 (2%)
	EXCORIATION	2 (2%)	1 (1%)	1 (1%)	4 (2%)
	FACIAL BONES FRACTURE	0 (0%)	0 (0%)	1 (1%)	1 (0%)
	FALL	1 (1%)	2 (2%)	1 (1%)	4 (2%)

1.) Only treatment emergent events related to lipids are displayed.

2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 2 and this is page value 2: 3

Body System or Organ Class	Dictionary-Derived Term	Placebo	Xanomeline Low Dose	Xanomeline High Dose	Total
		(N=86) n (%)	(N=96) n (%)	(N=72) n (%)	(N=254) n (%)
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	HIP FRACTURE	1 (1%)	0 (0%)	2 (3%)	3 (1%)
	JOINT DISLOCATION	0 (0%)	1 (1%)	0 (0%)	1 (0%)
	SKIN LACERATION	1 (1%)	2 (2%)	0 (0%)	3 (1%)
	WOUND	0 (0%)	1 (1%)	0 (0%)	1 (0%)
INVESTIGATIONS	ANY EVENT	10 (12%)	8 (8%)	5 (7%)	23 (9%)
	BIOPSY	0 (0%)	0 (0%)	1 (1%)	1 (0%)
	BIOPSY PROSTATE	0 (0%)	0 (0%)	1 (1%)	1 (0%)
	BLOOD ALKALINE	1 (1%)	0 (0%)	0 (0%)	1 (0%)
	PHOSPHATASE INCREASED				
	BLOOD CHOLESTEROL	0 (0%)	0 (0%)	1 (1%)	1 (0%)
	INCREASED				
	BLOOD CREATINE	1 (1%)	0 (0%)	0 (0%)	1 (0%)
	PHOSPHOKINASE				
	INCREASED				
	BLOOD GLUCOSE INCREASED	0 (0%)	1 (1%)	1 (1%)	2 (1%)
	BLOOD URINE PRESENT	1 (1%)	0 (0%)	0 (0%)	1 (0%)
	BODY TEMPERATURE	0 (0%)	1 (1%)	0 (0%)	1 (0%)
	INCREASED				

1.) Only treatment emergent events related to lipids are displayed.

2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 2 and this is page value 2: 3

Body System or Organ Class	Dictionary-Derived Term	Placebo	Xanomeline Low Dose	Xanomeline High Dose	Total
		(N=86) n (%)	(N=96) n (%)	(N=72) n (%)	(N=254) n (%)
INVESTIGATIONS	CYSTOSCOPY	1 (1%)	0 (0%)	0 (0%)	1 (0%)
	ELECTROCARDIOGRAM ST SEGMENT DEPRESSION	4 (5%)	1 (1%)	0 (0%)	5 (2%)
	ELECTROCARDIOGRAM T WAVE AMPLITUDE DECREASED	1 (1%)	1 (1%)	0 (0%)	2 (1%)
	ELECTROCARDIOGRAM T WAVE INVERSION	2 (2%)	1 (1%)	1 (1%)	4 (2%)
	HEART RATE INCREASED	1 (1%)	0 (0%)	0 (0%)	1 (0%)
	HEART RATE IRREGULAR	1 (1%)	0 (0%)	0 (0%)	1 (0%)
	NASAL MUCOSA BIOPSY	0 (0%)	1 (1%)	0 (0%)	1 (0%)
	NEUTROPHIL COUNT INCREASED	0 (0%)	1 (1%)	0 (0%)	1 (0%)
	URINE ANALYSIS ABNORMAL	0 (0%)	1 (1%)	0 (0%)	1 (0%)
	WEIGHT DECREASED	0 (0%)	1 (1%)	0 (0%)	1 (0%)
	WHITE BLOOD CELL COUNT INCREASED	0 (0%)	1 (1%)	0 (0%)	1 (0%)
METABOLISM AND NUTRITION DISORDERS	ANY EVENT	6 (7%)	1 (1%)	3 (4%)	10 (4%)
	DECREASED APPETITE	1 (1%)	0 (0%)	1 (1%)	2 (1%)
	DEHYDRATION	1 (1%)	0 (0%)	0 (0%)	1 (0%)
	DIABETES MELLITUS	1 (1%)	0 (0%)	0 (0%)	1 (0%)
	FOOD CRAVING	1 (1%)	1 (1%)	0 (0%)	2 (1%)

- 1.) Only treatment emergent events related to lipids are displayed.
- 2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 2 and this is page value 2: 3

Body System or Organ Class	Dictionary-Derived Term	Placebo		Xanomeline		Total (N=254)	
		(N=86)		Low Dose (N=96)			
		n	(%)	n	(%)		
METABOLISM AND NUTRITION DISORDERS	HYPERCHOLESTEROLAEMIA	0	(0%)	0	(0%)	1 (0%)	
	HYPONATRAEMIA	1	(1%)	0	(0%)	0 (0%)	
	INCREASED APPETITE	1	(1%)	0	(0%)	1 (1%)	
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS	ANY EVENT	5	(6%)	7	(7%)	8 (11%)	
	ARTHRALGIA	1	(1%)	2	(2%)	1 (1%)	
	ARTHRITIS	1	(1%)	0	(0%)	1 (1%)	
	BACK PAIN	1	(1%)	1	(1%)	3 (4%)	
	FLANK PAIN	0	(0%)	0	(0%)	2 (3%)	
	MUSCLE SPASMS	0	(0%)	1	(1%)	1 (1%)	
	MUSCULAR WEAKNESS	0	(0%)	1	(1%)	0 (0%)	
	MYALGIA	0	(0%)	0	(0%)	1 (0%)	
	PAIN IN EXTREMITY	1	(1%)	0	(0%)	0 (0%)	
						1 (0%)	

1.) Only treatment emergent events related to lipids are displayed.

2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 2 and this is page value 2: 3

Body System or Organ Class	Dictionary-Derived Term	Placebo (N=86) n (%)	Xanomeline Low Dose (N=96) n (%)	Xanomeline High Dose (N=72) n (%)	Total (N=254) n (%)
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS	SHOULDER PAIN	1 (1%)	2 (2%)	0 (0%)	3 (1%)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ANY EVENT	0 (0%)	2 (2%)	1 (1%)	3 (1%)
	COLON CANCER	0 (0%)	1 (1%)	0 (0%)	1 (0%)
	MALIGNANT FIBROUS HISTIOCYTOMA	0 (0%)	1 (1%)	0 (0%)	1 (0%)
	PROSTATE CANCER	0 (0%)	0 (0%)	1 (1%)	1 (0%)
NERVOUS SYSTEM DISORDERS	ANY EVENT	12 (14%)	22 (23%)	25 (35%)	59 (23%)
	AMNESIA	0 (0%)	0 (0%)	1 (1%)	1 (0%)
	BALANCE DISORDER	0 (0%)	1 (1%)	0 (0%)	1 (0%)
	BURNING SENSATION	0 (0%)	0 (0%)	2 (3%)	2 (1%)
	COGNITIVE DISORDER	0 (0%)	0 (0%)	1 (1%)	1 (0%)
	COMPLEX PARTIAL SEIZURES	0 (0%)	1 (1%)	0 (0%)	1 (0%)
	COORDINATION ABNORMAL	0 (0%)	1 (1%)	0 (0%)	1 (0%)
	DIZZINESS	2 (2%)	9 (9%)	11 (15%)	22 (9%)
	HEADACHE	7 (8%)	3 (3%)	6 (8%)	16 (6%)
	HEMIANOPIA HOMONYMOUS	0 (0%)	1 (1%)	0 (0%)	1 (0%)

- 1.) Only treatment emergent events related to lipids are displayed.  
 2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 2 and this is page value 2: 3

Body System or Organ Class	Dictionary-Derived Term	Placebo		Xanomeline		Total (N=254)	
		(N=86)		Low Dose (N=96)			
		n	(%)	n	(%)		
NERVOUS SYSTEM DISORDERS	HYPERSOMNIA	0	(0%)	0	(0%)	1 (0%)	
	LETHARGY	0	(0%)	1	(1%)	2 (1%)	
	PARAESTHESIA	0	(0%)	0	(0%)	1 (0%)	
	PARAESTHESIA ORAL	0	(0%)	1	(1%)	1 (0%)	
	PARKINSON'S DISEASE	1	(1%)	0	(0%)	1 (0%)	
	PAROSMIA	0	(0%)	0	(0%)	1 (0%)	
	PARTIAL SEIZURES WITH SECONDARY GENERALISATION	0	(0%)	0	(0%)	1 (0%)	
	PSYCHOMOTOR HYPERACTIVITY	1	(1%)	0	(0%)	1 (0%)	
	SOMNOLENCE	2	(2%)	3	(3%)	6 (2%)	
	STUPOR	0	(0%)	1	(1%)	1 (0%)	
	SYNCOPE	0	(0%)	5	(5%)	7 (3%)	
	SYNCOPE VASOVAGAL	0	(0%)	0	(0%)	1 (0%)	
	TRANSIENT ISCHAEMIC ATTACK	0	(0%)	2	(2%)	3 (1%)	
PSYCHIATRIC DISORDERS	ANY EVENT	10	(12%)	11	(11%)	29 (11%)	
	AGITATION	2	(2%)	3	(3%)	5 (2%)	
	ANXIETY	1	(1%)	3	(3%)	4 (2%)	
	COMPLETED SUICIDE	1	(1%)	0	(0%)	1 (0%)	
	CONFUSIONAL STATE	2	(2%)	3	(3%)	6 (2%)	

1.) Only treatment emergent events related to lipids are displayed.

2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 2 and this is page value 2: 3

Body System or Organ Class	Dictionary-Derived Term	Placebo (N=86)		Xanomeline		Total (N=254) n (%)
		n (%)	n (%)	Low Dose (N=96)	High Dose (N=72)	
PSYCHIATRIC DISORDERS	DELIRIUM	0 (0%)	0 (0%)	1 (1%)	1 (1%)	1 (0%)
	DELUSION	1 (1%)	0 (0%)	1 (1%)	1 (1%)	2 (1%)
	DEPRESSED MOOD	0 (0%)	1 (1%)	1 (1%)	1 (1%)	2 (1%)
	DISORIENTATION	1 (1%)	0 (0%)	0 (0%)	1 (0%)	1 (0%)
	HALLUCINATION	0 (0%)	0 (0%)	1 (1%)	1 (1%)	1 (0%)
	HALLUCINATION, VISUAL	0 (0%)	0 (0%)	1 (1%)	1 (1%)	1 (0%)
	INSOMNIA	2 (2%)	0 (0%)	2 (3%)	4 (2%)	4 (2%)
	IRRITABILITY	1 (1%)	1 (1%)	0 (0%)	2 (1%)	2 (1%)
	LIBIDO DECREASED	0 (0%)	0 (0%)	1 (1%)	1 (1%)	1 (0%)
	LISTLESS	0 (0%)	0 (0%)	1 (1%)	1 (1%)	1 (0%)
	NIGHTMARE	0 (0%)	0 (0%)	1 (1%)	1 (1%)	1 (0%)
	RESTLESSNESS	0 (0%)	1 (1%)	0 (0%)	1 (0%)	1 (0%)
RENAL AND URINARY DISORDERS	ANY EVENT	4 (5%)	4 (4%)	3 (4%)	11 (4%)	11 (4%)
	CALCULUS URETHRAL	0 (0%)	0 (0%)	1 (1%)	1 (0%)	1 (0%)
	DYSURIA	1 (1%)	1 (1%)	0 (0%)	2 (1%)	2 (1%)
	ENURESIS	0 (0%)	1 (1%)	0 (0%)	1 (0%)	1 (0%)
	INCONTINENCE	0 (0%)	1 (1%)	0 (0%)	1 (0%)	1 (0%)
	MICTURITION URGENCY	1 (1%)	1 (1%)	1 (1%)	3 (1%)	3 (1%)
	NEPHROLITHIASIS	1 (1%)	0 (0%)	1 (1%)	2 (1%)	2 (1%)
	POLLAKIURIA	1 (1%)	0 (0%)	0 (0%)	1 (0%)	1 (0%)

- 1.) Only treatment emergent events related to lipids are displayed.  
 2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 2 and this is page value 2: 3

Body System or Organ Class	Dictionary-Derived Term	Placebo (N=86)		Xanomeline Low Dose (N=96)		Xanomeline High Dose (N=72)		Total (N=254)
		n	(%)	n	(%)	n	(%)	
REPRODUCTIVE SYSTEM AND BREAST DISORDERS	ANY EVENT	2	(2%)	0	(0%)	1	(1%)	3 (1%)
	BENIGN PROSTATIC HYPERPLASIA	1	(1%)	0	(0%)	1	(1%)	2 (1%)
	PELVIC PAIN	1	(1%)	0	(0%)	0	(0%)	1 (0%)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	ANY EVENT	10	(12%)	10	(10%)	10	(14%)	30 (12%)
	ALLERGIC GRANULOMATOUS ANGIITIS	0	(0%)	0	(0%)	1	(1%)	1 (0%)
	COUGH	3	(3%)	6	(6%)	5	(7%)	14 (6%)
	DYSPHONIA	0	(0%)	1	(1%)	0	(0%)	1 (0%)
	DYSPNOEA	1	(1%)	1	(1%)	1	(1%)	3 (1%)
	EMPHYSEMA	1	(1%)	0	(0%)	0	(0%)	1 (0%)
	EPISTAXIS	0	(0%)	1	(1%)	2	(3%)	3 (1%)
	HAEMOPTYSIS	1	(1%)	0	(0%)	0	(0%)	1 (0%)

1.) Only treatment emergent events related to lipids are displayed.

2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 2 and this is page value 2: 3

Body System or Organ Class	Dictionary-Derived Term	Placebo (N=86) n (%)	Xanomeline Low Dose (N=96) n (%)	Xanomeline High Dose (N=72) n (%)	Total (N=254) n (%)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	NASAL CONGESTION	3 (3%)	1 (1%)	3 (4%)	7 (3%)
	PHARYNGEAL ERYTHEMA	0 (0%)	0 (0%)	1 (1%)	1 (0%)
	PHARYNGOLARYNGEAL PAIN	0 (0%)	1 (1%)	1 (1%)	2 (1%)
	POSTNASAL DRIP	1 (1%)	0 (0%)	0 (0%)	1 (0%)
	PRODUCTIVE COUGH	0 (0%)	0 (0%)	1 (1%)	1 (0%)
	RALES	1 (1%)	0 (0%)	0 (0%)	1 (0%)
	RESPIRATORY TRACT CONGESTION	0 (0%)	0 (0%)	1 (1%)	1 (0%)
	RHINORRHOEA	0 (0%)	1 (1%)	1 (1%)	2 (1%)
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	ANY EVENT	21 (24%)	42 (44%)	42 (58%)	105 (41%)
	ACTINIC KERATOSIS	0 (0%)	0 (0%)	1 (1%)	1 (0%)
	ALOPECIA	1 (1%)	0 (0%)	0 (0%)	1 (0%)
	BLISTER	0 (0%)	5 (5%)	1 (1%)	6 (2%)
	COLD SWEAT	1 (1%)	0 (0%)	0 (0%)	1 (0%)

- 1.) Only treatment emergent events related to lipids are displayed.
- 2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 2 and this is page value 2: 3

Body System or Organ Class	Dictionary-Derived Term	Placebo (N=86)		Xanomeline Low Dose (N=96)		Xanomeline High Dose (N=72)		Total (N=254)
		n	(%)	n	(%)	n	(%)	
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	DERMATITIS ATOPIC	1	(1%)	0	(0%)	0	(0%)	1 (0%)
	DERMATITIS CONTACT	0	(0%)	1	(1%)	0	(0%)	1 (0%)
	DRUG ERUPTION	1	(1%)	0	(0%)	0	(0%)	1 (0%)
	ERYTHEMA	9	(10%)	15	(16%)	14	(19%)	38 (15%)
	HYPERHIDROSIS	2	(2%)	4	(4%)	8	(11%)	14 (6%)
	PRURITUS	8	(9%)	23	(24%)	26	(36%)	57 (22%)
	PRURITUS GENERALISED	0	(0%)	1	(1%)	1	(1%)	2 (1%)
	RASH	5	(6%)	13	(14%)	11	(15%)	29 (11%)
	RASH ERYTHEMATOUS	0	(0%)	2	(2%)	0	(0%)	2 (1%)
	RASH MACULO-PAPULAR	0	(0%)	0	(0%)	1	(1%)	1 (0%)
	RASH PAPULAR	0	(0%)	0	(0%)	1	(1%)	1 (0%)
	RASH PRURITIC	0	(0%)	1	(1%)	2	(3%)	3 (1%)
	SKIN EXFOLIATION	0	(0%)	1	(1%)	0	(0%)	1 (0%)
	SKIN IRRITATION	3	(3%)	6	(6%)	5	(7%)	14 (6%)
	SKIN ODOUR ABNORMAL	0	(0%)	0	(0%)	1	(1%)	1 (0%)
	SKIN ULCER	1	(1%)	0	(0%)	0	(0%)	1 (0%)
	URTICARIA	0	(0%)	1	(1%)	1	(1%)	2 (1%)
SOCIAL CIRCUMSTANCES	ANY EVENT	0	(0%)	0	(0%)	1	(1%)	1 (0%)
	ALCOHOL USE	0	(0%)	0	(0%)	1	(1%)	1 (0%)
SURGICAL AND MEDICAL PROCEDURES	ANY EVENT	2	(2%)	1	(1%)	2	(3%)	5 (2%)
	ACROCHORDON EXCISION	0	(0%)	0	(0%)	1	(1%)	1 (0%)

- 1.) Only treatment emergent events related to lipids are displayed.
- 2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 2 and this is page value 2: 3

Body System or Organ Class	Dictionary-Derived Term	Placebo		Xanomeline		Total (N=254)
		n	(%)	n	(%)	
SURGICAL AND MEDICAL PROCEDURES	CATARACT OPERATION	1	(1%)	1	(1%)	0 (0%)
	EYE LASER SURGERY	1	(1%)	0	(0%)	0 (0%)
	SKIN LESION EXCISION	0	(0%)	0	(0%)	1 (1%)
VASCULAR DISORDERS	ANY EVENT	3	(3%)	4	(4%)	1 (1%)
	HOT FLUSH	0	(0%)	1	(1%)	0 (0%)
	HYPERTENSION	1	(1%)	2	(2%)	0 (0%)
	HYPOTENSION	2	(2%)	1	(1%)	0 (0%)
	ORTHOSTATIC HYPOTENSION	1	(1%)	0	(0%)	0 (0%)
	WOUND HAEMORRHAGE	0	(0%)	0	(0%)	1 (1%)

- 1.) Only treatment emergent events related to lipids are displayed.  
 2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 2 and this is page value 2: 4

Body System or Organ Class	Dictionary-Derived Term	Placebo	Xanomeline Low Dose	Xanomeline High Dose	Total
		(N=86)	(N=96)	(N=72)	(N=254)
n (%)	n (%)	n (%)	n (%)	n (%)	
ANY EVENT	ANY EVENT	69 (80%)	86 (90%)	70 (97%)	225 (89%)
CARDIAC DISORDERS	ANY EVENT	13 (15%)	16 (17%)	15 (21%)	44 (17%)
	ATRIAL FIBRILLATION	1 (1%)	2 (2%)	2 (3%)	5 (2%)
	ATRIAL FLUTTER	0 (0%)	1 (1%)	1 (1%)	2 (1%)
	ATRIAL HYPERTROPHY	1 (1%)	0 (0%)	0 (0%)	1 (0%)
	ATRIOVENTRICULAR BLOCK	1 (1%)	1 (1%)	0 (0%)	2 (1%)
	FIRST DEGREE				
	ATRIOVENTRICULAR BLOCK	2 (2%)	2 (2%)	1 (1%)	5 (2%)
	SECOND DEGREE				
	BRADYCARDIA	1 (1%)	0 (0%)	0 (0%)	1 (0%)
	BUNDLE BRANCH BLOCK	1 (1%)	0 (0%)	0 (0%)	1 (0%)
	LEFT				
	BUNDLE BRANCH BLOCK	1 (1%)	1 (1%)	0 (0%)	2 (1%)
	RIGHT				
	CARDIAC DISORDER	0 (0%)	0 (0%)	1 (1%)	1 (0%)
	CARDIAC FAILURE	1 (1%)	0 (0%)	0 (0%)	1 (0%)
	CONGESTIVE				
	MYOCARDIAL INFARCTION	4 (5%)	2 (2%)	4 (6%)	10 (4%)
	PALPITATIONS	0 (0%)	2 (2%)	0 (0%)	2 (1%)
	SINUS ARRHYTHMIA	1 (1%)	0 (0%)	0 (0%)	1 (0%)
	SINUS BRADYCARDIA	2 (2%)	7 (7%)	8 (11%)	17 (7%)
	SUPRAVENTRICULAR	1 (1%)	1 (1%)	1 (1%)	3 (1%)
	EXTRASYSTOLES				

- 1.) Only treatment emergent events related to lipids are displayed.  
 2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 2 and this is page value 2: 4

Body System or Organ Class	Dictionary-Derived Term	Placebo	Xanomeline	Xanomeline	Total
		(N=86) n (%)	Low Dose (N=96) n (%)	High Dose (N=72) n (%)	(N=254) n (%)
CARDIAC DISORDERS	SUPRAVENTRICULAR TACHYCARDIA	0 (0%)	1 (1%)	0 (0%)	1 (0%)
	TACHYCARDIA	1 (1%)	0 (0%)	0 (0%)	1 (0%)
	VENTRICULAR EXTRASYSTOLES	0 (0%)	2 (2%)	1 (1%)	3 (1%)
	VENTRICULAR HYPERTROPHY	1 (1%)	0 (0%)	0 (0%)	1 (0%)
	WOLFF-PARKINSON-WHITE SYNDROME	0 (0%)	1 (1%)	0 (0%)	1 (0%)
CONGENITAL, FAMILIAL AND GENETIC DISORDERS	ANY EVENT	0 (0%)	1 (1%)	2 (3%)	3 (1%)
	VENTRICULAR SEPTAL DEFECT	0 (0%)	1 (1%)	2 (3%)	3 (1%)
EAR AND LABYRINTH DISORDERS	ANY EVENT	1 (1%)	2 (2%)	1 (1%)	4 (2%)
	CERUMEN IMPACTION	0 (0%)	1 (1%)	0 (0%)	1 (0%)
	EAR PAIN	1 (1%)	0 (0%)	0 (0%)	1 (0%)
	TINNITUS	0 (0%)	1 (1%)	0 (0%)	1 (0%)
	VERTIGO	0 (0%)	1 (1%)	1 (1%)	2 (1%)
EYE DISORDERS	ANY EVENT	4 (5%)	2 (2%)	1 (1%)	7 (3%)
	CONJUNCTIVAL HAEMORRHAGE	0 (0%)	1 (1%)	0 (0%)	1 (0%)

- 1.) Only treatment emergent events related to lipids are displayed.  
 2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 2 and this is page value 2: 4

Body System or Organ Class	Dictionary-Derived Term	Placebo		Xanomeline		Total (N=254)			
		(N=86)		Low Dose (N=96)					
		n	(%)	n	(%)				
EYE DISORDERS	CONJUNCTIVITIS	2	(2%)	0	(0%)	0	(0%)	2	(1%)
	EYE ALLERGY	1	(1%)	0	(0%)	0	(0%)	1	(0%)
	EYE PRURITUS	1	(1%)	0	(0%)	0	(0%)	1	(0%)
	EYE SWELLING	1	(1%)	0	(0%)	0	(0%)	1	(0%)
	GLAUCOMA	1	(1%)	0	(0%)	0	(0%)	1	(0%)
	VISION BLURRED	0	(0%)	1	(1%)	1	(1%)	2	(1%)
GASTROINTESTINAL DISORDERS	ANY EVENT	17	(20%)	16	(17%)	20	(28%)	53	(21%)
	ABDOMINAL DISCOMFORT	0	(0%)	0	(0%)	1	(1%)	1	(0%)
	ABDOMINAL PAIN	1	(1%)	3	(3%)	1	(1%)	5	(2%)
	CONSTIPATION	1	(1%)	0	(0%)	0	(0%)	1	(0%)
	DIARRHOEA	9	(10%)	6	(6%)	3	(4%)	18	(7%)
	DYSPEPSIA	1	(1%)	1	(1%)	1	(1%)	3	(1%)
	DYSPHAGIA	0	(0%)	1	(1%)	0	(0%)	1	(0%)
	FLATULENCE	1	(1%)	0	(0%)	0	(0%)	1	(0%)
	GASTROINTESTINAL HAEMORRHAGE	0	(0%)	0	(0%)	1	(1%)	1	(0%)
	GASTROOESOPHAGEAL REFLUX DISEASE	1	(1%)	0	(0%)	0	(0%)	1	(0%)
	GLOSSITIS	1	(1%)	0	(0%)	0	(0%)	1	(0%)
	HIATUS HERNIA	1	(1%)	0	(0%)	0	(0%)	1	(0%)
	NAUSEA	3	(3%)	3	(3%)	6	(8%)	12	(5%)
	RECTAL HAEMORRHAGE	0	(0%)	1	(1%)	0	(0%)	1	(0%)

- 1.) Only treatment emergent events related to lipids are displayed.
- 2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 2 and this is page value 2: 4

Body System or Organ Class	Dictionary-Derived Term	Placebo		Xanomeline		Total (N=254)	
		(N=86)		Low Dose (N=96)			
		n	(%)	n	(%)		
GASTROINTESTINAL DISORDERS	SALIVARY HYPERSECRETION	0	(0%)	0	(0%)	4 (6%)	
	STOMACH DISCOMFORT	0	(0%)	0	(0%)	1 (1%)	
	VOMITING	3	(3%)	4	(4%)	6 (8%)	
						13 (5%)	
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	ANY EVENT	21	(24%)	51	(53%)	36 (50%)	
	APPLICATION SITE BLEEDING	0	(0%)	1	(1%)	0 (0%)	
	APPLICATION SITE DERMATITIS	5	(6%)	9	(9%)	7 (10%)	
	APPLICATION SITE DESQUAMATION	0	(0%)	1	(1%)	0 (0%)	
	APPLICATION SITE DISCHARGE	0	(0%)	0	(0%)	1 (1%)	
	APPLICATION SITE DISCOLOURATION	0	(0%)	1	(1%)	0 (0%)	
	APPLICATION SITE ERYTHEMA	3	(3%)	13	(14%)	14 (19%)	
	APPLICATION SITE INDURATION	1	(1%)	0	(0%)	0 (0%)	
	APPLICATION SITE IRRITATION	3	(3%)	9	(9%)	9 (12%)	
						21 (8%)	

1.) Only treatment emergent events related to lipids are displayed.

2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 2 and this is page value 2: 4

Body System or Organ Class	Dictionary-Derived Term	Placebo (N=86)		Xanomeline Low Dose (N=96)		Xanomeline High Dose (N=72)		Total (N=254)
		n	(%)	n	(%)	n	(%)	
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	APPLICATION SITE PAIN	0	(0%)	0	(0%)	2	(3%)	2 (1%)
	APPLICATION SITE PERSPIRATION	0	(0%)	0	(0%)	2	(3%)	2 (1%)
	APPLICATION SITE PRURITUS	6	(7%)	23	(24%)	21	(29%)	50 (20%)
	APPLICATION SITE REACTION	1	(1%)	0	(0%)	1	(1%)	2 (1%)
	APPLICATION SITE SWELLING	0	(0%)	1	(1%)	2	(3%)	3 (1%)
	APPLICATION SITE URTICARIA	0	(0%)	2	(2%)	1	(1%)	3 (1%)
	APPLICATION SITE VESICLES	1	(1%)	5	(5%)	5	(7%)	11 (4%)
	APPLICATION SITE WARMTH	0	(0%)	1	(1%)	0	(0%)	1 (0%)
	ASTHENIA	1	(1%)	1	(1%)	0	(0%)	2 (1%)
	CHEST DISCOMFORT	0	(0%)	1	(1%)	1	(1%)	2 (1%)
	CHEST PAIN	0	(0%)	0	(0%)	2	(3%)	2 (1%)
	CHILLS	1	(1%)	1	(1%)	1	(1%)	3 (1%)

- 1.) Only treatment emergent events related to lipids are displayed.
- 2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 2 and this is page value 2: 4

Body System or Organ Class	Dictionary-Derived Term	Placebo		Xanomeline		Xanomeline		Total (N=254)	
		(N=86)		Low Dose (N=96)		High Dose (N=72)			
		n	(%)	n	(%)	n	(%)		
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	CYST	0	(0%)	1	(1%)	0	(0%)	1 (0%)	
	FATIGUE	1	(1%)	5	(5%)	5	(7%)	11 (4%)	
	FEELING ABNORMAL	0	(0%)	0	(0%)	1	(1%)	1 (0%)	
	FEELING COLD	0	(0%)	0	(0%)	1	(1%)	1 (0%)	
	INFLAMMATION	0	(0%)	1	(1%)	0	(0%)	1 (0%)	
	MALAISE	0	(0%)	1	(1%)	2	(3%)	3 (1%)	
	OEDEMA	0	(0%)	2	(2%)	0	(0%)	2 (1%)	
	OEDEMA PERIPHERAL	2	(2%)	1	(1%)	2	(3%)	5 (2%)	
	PAIN	0	(0%)	1	(1%)	1	(1%)	2 (1%)	
	PYREXIA	2	(2%)	1	(1%)	0	(0%)	3 (1%)	
	SECRETION DISCHARGE	0	(0%)	1	(1%)	0	(0%)	1 (0%)	

1.) Only treatment emergent events related to lipids are displayed.

2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 2 and this is page value 2: 4

Body System or Organ Class	Dictionary-Derived Term	Placebo		Xanomeline		Total (N=254)	
		(N=86)		Low Dose (N=96)			
		n	(%)	n	(%)		
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	SUDDEN DEATH	0	(0%)	1	(1%)	0 (0%)	
	SWELLING	0	(0%)	1	(1%)	0 (0%)	
	ULCER	0	(0%)	1	(1%)	0 (0%)	
HEPATOBILIARY DISORDERS	ANY EVENT	1	(1%)	0	(0%)	0 (0%)	
	HYPERBILIRUBINAEMIA	1	(1%)	0	(0%)	0 (0%)	
IMMUNE SYSTEM DISORDERS	ANY EVENT	0	(0%)	1	(1%)	1 (0%)	
	HYPERSENSITIVITY	0	(0%)	1	(1%)	0 (0%)	
	SEASONAL ALLERGY	0	(0%)	0	(0%)	1 (0%)	
INFECTIONS AND INFESTATIONS	ANY EVENT	16	(19%)	10	(10%)	13 (18%)	
	BRONCHITIS	1	(1%)	0	(0%)	0 (0%)	
	CELLULITIS	0	(0%)	1	(1%)	0 (0%)	
	CERVICITIS	1	(1%)	0	(0%)	0 (0%)	
	CYSTITIS	1	(1%)	0	(0%)	1 (1%)	
	EAR INFECTION	2	(2%)	0	(0%)	0 (0%)	
	GASTROENTERITIS VIRAL	1	(1%)	0	(0%)	0 (0%)	
	HORDEOLUM	0	(0%)	0	(0%)	1 (1%)	
	INFLUENZA	1	(1%)	1	(1%)	1 (1%)	

- 1.) Only treatment emergent events related to lipids are displayed.
- 2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 2 and this is page value 2: 4

Body System or Organ Class	Dictionary-Derived Term	Placebo	Xanomeline Low Dose	Xanomeline High Dose	Total
		(N=86) n (%)	(N=96) n (%)	(N=72) n (%)	(N=254) n (%)
INFECTIONS AND INFESTATIONS	LOCALISED INFECTION	1 (1%)	1 (1%)	0 (0%)	2 (1%)
	LOWER RESPIRATORY TRACT INFECTION	0 (0%)	0 (0%)	1 (1%)	1 (0%)
	NASOPHARYNGITIS	2 (2%)	4 (4%)	6 (8%)	12 (5%)
	ONYCHOMYCOSIS	0 (0%)	1 (1%)	0 (0%)	1 (0%)
	PNEUMONIA	0 (0%)	1 (1%)	0 (0%)	1 (0%)
	RHINITIS	0 (0%)	0 (0%)	1 (1%)	1 (0%)
	UPPER RESPIRATORY TRACT INFECTION	6 (7%)	1 (1%)	3 (4%)	10 (4%)
	URINARY TRACT INFECTION	2 (2%)	0 (0%)	1 (1%)	3 (1%)
	VAGINAL MYCOSIS	1 (1%)	0 (0%)	0 (0%)	1 (0%)
	VIRAL INFECTION	0 (0%)	1 (1%)	0 (0%)	1 (0%)
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	ANY EVENT	4 (5%)	5 (5%)	5 (7%)	14 (6%)
	CONTUSION	1 (1%)	1 (1%)	2 (3%)	4 (2%)
	EXCORIATION	2 (2%)	1 (1%)	1 (1%)	4 (2%)
	FACIAL BONES FRACTURE	0 (0%)	0 (0%)	1 (1%)	1 (0%)
	FALL	1 (1%)	2 (2%)	1 (1%)	4 (2%)

1.) Only treatment emergent events related to lipids are displayed.

2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 2 and this is page value 2: 4

Body System or Organ Class	Dictionary-Derived Term	Placebo (N=86)		Xanomeline Low Dose (N=96)		Xanomeline High Dose (N=72)		Total (N=254)
		n	(%)	n	(%)	n	(%)	
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	HIP FRACTURE	1	(1%)	0	(0%)	2	(3%)	3 (1%)
	JOINT DISLOCATION	0	(0%)	1	(1%)	0	(0%)	1 (0%)
	SKIN LACERATION	1	(1%)	2	(2%)	0	(0%)	3 (1%)
	WOUND	0	(0%)	1	(1%)	0	(0%)	1 (0%)
INVESTIGATIONS	ANY EVENT	10	(12%)	8	(8%)	5	(7%)	23 (9%)
	BIOPSY	0	(0%)	0	(0%)	1	(1%)	1 (0%)
	BIOPSY PROSTATE	0	(0%)	0	(0%)	1	(1%)	1 (0%)
	BLOOD ALKALINE PHOSPHATASE INCREASED	1	(1%)	0	(0%)	0	(0%)	1 (0%)
	BLOOD CHOLESTEROL INCREASED	0	(0%)	0	(0%)	1	(1%)	1 (0%)
	BLOOD CREATINE PHOSPHOKINASE INCREASED	1	(1%)	0	(0%)	0	(0%)	1 (0%)
	BLOOD GLUCOSE INCREASED	0	(0%)	1	(1%)	1	(1%)	2 (1%)
	BLOOD URINE PRESENT	1	(1%)	0	(0%)	0	(0%)	1 (0%)
	BODY TEMPERATURE INCREASED	0	(0%)	1	(1%)	0	(0%)	1 (0%)

1.) Only treatment emergent events related to lipids are displayed.

2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 2 and this is page value 2: 4

Body System or Organ Class	Dictionary-Derived Term	Placebo		Xanomeline		Total (N=254)	
		(N=86)		Low Dose (N=96)			
		n	(%)	n	(%)		
INVESTIGATIONS	CYSTOSCOPY	1	(1%)	0	(0%)	0 (0%)	
	ELECTROCARDIOGRAM ST SEGMENT DEPRESSION	4	(5%)	1	(1%)	0 (0%)	
	ELECTROCARDIOGRAM T WAVE AMPLITUDE DECREASED	1	(1%)	1	(1%)	0 (0%)	
	ELECTROCARDIOGRAM T WAVE INVERSION	2	(2%)	1	(1%)	1 (1%)	
	HEART RATE INCREASED	1	(1%)	0	(0%)	1 (0%)	
	HEART RATE IRREGULAR	1	(1%)	0	(0%)	0 (0%)	
	NASAL MUCOSA BIOPSY	0	(0%)	1	(1%)	1 (0%)	
	NEUTROPHIL COUNT INCREASED	0	(0%)	1	(1%)	0 (0%)	
	URINE ANALYSIS ABNORMAL	0	(0%)	1	(1%)	1 (0%)	
	WEIGHT DECREASED	0	(0%)	1	(1%)	0 (0%)	
	WHITE BLOOD CELL COUNT INCREASED	0	(0%)	1	(1%)	1 (0%)	
METABOLISM AND NUTRITION DISORDERS	ANY EVENT	6	(7%)	1	(1%)	3 (4%)	
	DECREASED APPETITE	1	(1%)	0	(0%)	1 (1%)	
	DEHYDRATION	1	(1%)	0	(0%)	0 (0%)	
	DIABETES MELLITUS	1	(1%)	0	(0%)	1 (0%)	
	FOOD CRAVING	1	(1%)	1	(1%)	0 (0%)	

- 1.) Only treatment emergent events related to lipids are displayed.
- 2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 2 and this is page value 2: 4

Body System or Organ Class	Dictionary-Derived Term	Placebo		Xanomeline		Total (N=254)	
		(N=86)		Low Dose (N=96)			
		n	(%)	n	(%)		
METABOLISM AND NUTRITION DISORDERS	HYPERCHOLESTEROLAEMIA	0	(0%)	0	(0%)	1 (0%)	
	HYPONATRAEMIA	1	(1%)	0	(0%)	0 (0%)	
	INCREASED APPETITE	1	(1%)	0	(0%)	1 (1%)	
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS	ANY EVENT	5	(6%)	7	(7%)	8 (11%)	
	ARTHRALGIA	1	(1%)	2	(2%)	1 (1%)	
	ARTHRITIS	1	(1%)	0	(0%)	1 (1%)	
	BACK PAIN	1	(1%)	1	(1%)	3 (4%)	
	FLANK PAIN	0	(0%)	0	(0%)	2 (3%)	
	MUSCLE SPASMS	0	(0%)	1	(1%)	1 (1%)	
	MUSCULAR WEAKNESS	0	(0%)	1	(1%)	0 (0%)	
	MYALGIA	0	(0%)	0	(0%)	1 (0%)	
	PAIN IN EXTREMITY	1	(1%)	0	(0%)	0 (0%)	

1.) Only treatment emergent events related to lipids are displayed.

2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 2 and this is page value 2: 4

Body System or Organ Class	Dictionary-Derived Term	Placebo (N=86) n (%)	Xanomeline Low Dose (N=96) n (%)	Xanomeline High Dose (N=72) n (%)	Total (N=254) n (%)
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS	SHOULDER PAIN	1 (1%)	2 (2%)	0 (0%)	3 (1%)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	ANY EVENT	0 (0%)	2 (2%)	1 (1%)	3 (1%)
	COLON CANCER	0 (0%)	1 (1%)	0 (0%)	1 (0%)
	MALIGNANT FIBROUS HISTIOCYTOMA	0 (0%)	1 (1%)	0 (0%)	1 (0%)
	PROSTATE CANCER	0 (0%)	0 (0%)	1 (1%)	1 (0%)
NERVOUS SYSTEM DISORDERS	ANY EVENT	12 (14%)	22 (23%)	25 (35%)	59 (23%)
	AMNESIA	0 (0%)	0 (0%)	1 (1%)	1 (0%)
	BALANCE DISORDER	0 (0%)	1 (1%)	0 (0%)	1 (0%)
	BURNING SENSATION	0 (0%)	0 (0%)	2 (3%)	2 (1%)
	COGNITIVE DISORDER	0 (0%)	0 (0%)	1 (1%)	1 (0%)
	COMPLEX PARTIAL SEIZURES	0 (0%)	1 (1%)	0 (0%)	1 (0%)
	COORDINATION ABNORMAL	0 (0%)	1 (1%)	0 (0%)	1 (0%)
	DIZZINESS	2 (2%)	9 (9%)	11 (15%)	22 (9%)
	HEADACHE	7 (8%)	3 (3%)	6 (8%)	16 (6%)
	HEMIANOPIA HOMONYMOUS	0 (0%)	1 (1%)	0 (0%)	1 (0%)

- 1.) Only treatment emergent events related to lipids are displayed.  
 2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 2 and this is page value 2: 4

Body System or Organ Class	Dictionary-Derived Term	Placebo (N=86)		Xanomeline (N=96)		Xanomeline (N=72)		Total (N=254)
		n	(%)	n	(%)	n	(%)	
NERVOUS SYSTEM DISORDERS	HYPERSOMNIA	0	(0%)	0	(0%)	1	(1%)	1 (0%)
	LETHARGY	0	(0%)	1	(1%)	1	(1%)	2 (1%)
	PARAESTHESIA	0	(0%)	0	(0%)	1	(1%)	1 (0%)
	PARAESTHESIA ORAL	0	(0%)	1	(1%)	0	(0%)	1 (0%)
	PARKINSON'S DISEASE	1	(1%)	0	(0%)	0	(0%)	1 (0%)
	PAROSMIA	0	(0%)	0	(0%)	1	(1%)	1 (0%)
	PARTIAL SEIZURES WITH SECONDARY GENERALISATION	0	(0%)	0	(0%)	1	(1%)	1 (0%)
	PSYCHOMOTOR HYPERACTIVITY	1	(1%)	0	(0%)	0	(0%)	1 (0%)
	SOMNOLENCE	2	(2%)	3	(3%)	1	(1%)	6 (2%)
	STUPOR	0	(0%)	1	(1%)	0	(0%)	1 (0%)
	SYNCOPE	0	(0%)	5	(5%)	2	(3%)	7 (3%)
	SYNCOPE VASOVAGAL	0	(0%)	0	(0%)	1	(1%)	1 (0%)
	TRANSIENT ISCHAEMIC ATTACK	0	(0%)	2	(2%)	1	(1%)	3 (1%)
PSYCHIATRIC DISORDERS	ANY EVENT	10	(12%)	11	(11%)	8	(11%)	29 (11%)
	AGITATION	2	(2%)	3	(3%)	0	(0%)	5 (2%)
	ANXIETY	1	(1%)	3	(3%)	0	(0%)	4 (2%)
	COMPLETED SUICIDE	1	(1%)	0	(0%)	0	(0%)	1 (0%)
	CONFUSIONAL STATE	2	(2%)	3	(3%)	1	(1%)	6 (2%)

1.) Only treatment emergent events related to lipids are displayed.

2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 2 and this is page value 2: 4

Body System or Organ Class	Dictionary-Derived Term	Placebo (N=86)		Xanomeline		Total (N=254) n (%)
		n (%)	n (%)	Low Dose (N=96)	High Dose (N=72)	
PSYCHIATRIC DISORDERS	DELIRIUM	0 (0%)	0 (0%)	1 (1%)	1 (1%)	1 (0%)
	DELUSION	1 (1%)	0 (0%)	1 (1%)	1 (1%)	2 (1%)
	DEPRESSED MOOD	0 (0%)	1 (1%)	1 (1%)	1 (1%)	2 (1%)
	DISORIENTATION	1 (1%)	0 (0%)	0 (0%)	1 (0%)	1 (0%)
	HALLUCINATION	0 (0%)	0 (0%)	1 (1%)	1 (1%)	1 (0%)
	HALLUCINATION, VISUAL	0 (0%)	0 (0%)	1 (1%)	1 (1%)	1 (0%)
	INSOMNIA	2 (2%)	0 (0%)	2 (3%)	4 (2%)	4 (2%)
	IRRITABILITY	1 (1%)	1 (1%)	0 (0%)	2 (1%)	2 (1%)
	LIBIDO DECREASED	0 (0%)	0 (0%)	1 (1%)	1 (1%)	1 (0%)
	LISTLESS	0 (0%)	0 (0%)	1 (1%)	1 (1%)	1 (0%)
	NIGHTMARE	0 (0%)	0 (0%)	1 (1%)	1 (1%)	1 (0%)
	RESTLESSNESS	0 (0%)	1 (1%)	0 (0%)	1 (0%)	1 (0%)
RENAL AND URINARY DISORDERS	ANY EVENT	4 (5%)	4 (4%)	3 (4%)	11 (4%)	11 (4%)
	CALCULUS URETHRAL	0 (0%)	0 (0%)	1 (1%)	1 (0%)	1 (0%)
	DYSURIA	1 (1%)	1 (1%)	0 (0%)	2 (1%)	2 (1%)
	ENURESIS	0 (0%)	1 (1%)	0 (0%)	1 (0%)	1 (0%)
	INCONTINENCE	0 (0%)	1 (1%)	0 (0%)	1 (0%)	1 (0%)
	MICTURITION URGENCY	1 (1%)	1 (1%)	1 (1%)	3 (1%)	3 (1%)
	NEPHROLITHIASIS	1 (1%)	0 (0%)	1 (1%)	2 (1%)	2 (1%)
	POLLAKIURIA	1 (1%)	0 (0%)	0 (0%)	1 (0%)	1 (0%)

- 1.) Only treatment emergent events related to lipids are displayed.  
 2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 2 and this is page value 2: 4

Body System or Organ Class	Dictionary-Derived Term	Placebo (N=86)		Xanomeline Low Dose (N=96)		Xanomeline High Dose (N=72)		Total (N=254)
		n	(%)	n	(%)	n	(%)	
REPRODUCTIVE SYSTEM AND BREAST DISORDERS	ANY EVENT	2	(2%)	0	(0%)	1	(1%)	3 (1%)
	BENIGN PROSTATIC HYPERPLASIA	1	(1%)	0	(0%)	1	(1%)	2 (1%)
	PELVIC PAIN	1	(1%)	0	(0%)	0	(0%)	1 (0%)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	ANY EVENT	10	(12%)	10	(10%)	10	(14%)	30 (12%)
	ALLERGIC GRANULOMATOUS ANGIITIS	0	(0%)	0	(0%)	1	(1%)	1 (0%)
	COUGH	3	(3%)	6	(6%)	5	(7%)	14 (6%)
	DYSPHONIA	0	(0%)	1	(1%)	0	(0%)	1 (0%)
	DYSPNOEA	1	(1%)	1	(1%)	1	(1%)	3 (1%)
	EMPHYSEMA	1	(1%)	0	(0%)	0	(0%)	1 (0%)
	EPISTAXIS	0	(0%)	1	(1%)	2	(3%)	3 (1%)
	HAEMOPTYSIS	1	(1%)	0	(0%)	0	(0%)	1 (0%)

- 1.) Only treatment emergent events related to lipids are displayed.  
 2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 2 and this is page value 2: 4

Body System or Organ Class	Dictionary-Derived Term	Placebo (N=86) n (%)	Xanomeline Low Dose (N=96) n (%)	Xanomeline High Dose (N=72) n (%)	Total (N=254) n (%)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	NASAL CONGESTION	3 (3%)	1 (1%)	3 (4%)	7 (3%)
	PHARYNGEAL ERYTHEMA	0 (0%)	0 (0%)	1 (1%)	1 (0%)
	PHARYNGOLARYNGEAL PAIN	0 (0%)	1 (1%)	1 (1%)	2 (1%)
	POSTNASAL DRIP	1 (1%)	0 (0%)	0 (0%)	1 (0%)
	PRODUCTIVE COUGH	0 (0%)	0 (0%)	1 (1%)	1 (0%)
	RALES	1 (1%)	0 (0%)	0 (0%)	1 (0%)
	RESPIRATORY TRACT CONGESTION	0 (0%)	0 (0%)	1 (1%)	1 (0%)
	RHINORRHOEA	0 (0%)	1 (1%)	1 (1%)	2 (1%)
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	ANY EVENT	21 (24%)	42 (44%)	42 (58%)	105 (41%)
	ACTINIC KERATOSIS	0 (0%)	0 (0%)	1 (1%)	1 (0%)
	ALOPECIA	1 (1%)	0 (0%)	0 (0%)	1 (0%)
	BLISTER	0 (0%)	5 (5%)	1 (1%)	6 (2%)
	COLD SWEAT	1 (1%)	0 (0%)	0 (0%)	1 (0%)

- 1.) Only treatment emergent events related to lipids are displayed.
- 2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 2 and this is page value 2: 4

Body System or Organ Class	Dictionary-Derived Term	Placebo (N=86)		Xanomeline Low Dose (N=96)		Xanomeline High Dose (N=72)		Total (N=254)
		n	(%)	n	(%)	n	(%)	
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	DERMATITIS ATOPIC	1	(1%)	0	(0%)	0	(0%)	1 (0%)
	DERMATITIS CONTACT	0	(0%)	1	(1%)	0	(0%)	1 (0%)
	DRUG ERUPTION	1	(1%)	0	(0%)	0	(0%)	1 (0%)
	ERYTHEMA	9	(10%)	15	(16%)	14	(19%)	38 (15%)
	HYPERHIDROSIS	2	(2%)	4	(4%)	8	(11%)	14 (6%)
	PRURITUS	8	(9%)	23	(24%)	26	(36%)	57 (22%)
	PRURITUS GENERALISED	0	(0%)	1	(1%)	1	(1%)	2 (1%)
	RASH	5	(6%)	13	(14%)	11	(15%)	29 (11%)
	RASH ERYTHEMATOUS	0	(0%)	2	(2%)	0	(0%)	2 (1%)
	RASH MACULO-PAPULAR	0	(0%)	0	(0%)	1	(1%)	1 (0%)
	RASH PAPULAR	0	(0%)	0	(0%)	1	(1%)	1 (0%)
	RASH PRURITIC	0	(0%)	1	(1%)	2	(3%)	3 (1%)
	SKIN EXFOLIATION	0	(0%)	1	(1%)	0	(0%)	1 (0%)
	SKIN IRRITATION	3	(3%)	6	(6%)	5	(7%)	14 (6%)
	SKIN ODOUR ABNORMAL	0	(0%)	0	(0%)	1	(1%)	1 (0%)
	SKIN ULCER	1	(1%)	0	(0%)	0	(0%)	1 (0%)
	URTICARIA	0	(0%)	1	(1%)	1	(1%)	2 (1%)
SOCIAL CIRCUMSTANCES	ANY EVENT	0	(0%)	0	(0%)	1	(1%)	1 (0%)
	ALCOHOL USE	0	(0%)	0	(0%)	1	(1%)	1 (0%)
SURGICAL AND MEDICAL PROCEDURES	ANY EVENT	2	(2%)	1	(1%)	2	(3%)	5 (2%)
	ACROCHORDON EXCISION	0	(0%)	0	(0%)	1	(1%)	1 (0%)

- 1.) Only treatment emergent events related to lipids are displayed.
- 2.) Subjects are only counted once within each body system and preferred term.

Table 14: Summary of Treatment Emergent Adverse Events

This is page value 1: 2 and this is page value 2: 4

Body System or Organ Class	Dictionary-Derived Term	Placebo (N=86) n (%)	Xanomeline Low Dose (N=96) n (%)	Xanomeline High Dose (N=72) n (%)	Total (N=254) n (%)
SURGICAL AND MEDICAL PROCEDURES	CATARACT OPERATION	1 (1%)	1 (1%)	0 (0%)	2 (1%)
	EYE LASER SURGERY	1 (1%)	0 (0%)	0 (0%)	1 (0%)
	SKIN LESION EXCISION	0 (0%)	0 (0%)	1 (1%)	1 (0%)
VASCULAR DISORDERS	ANY EVENT	3 (3%)	4 (4%)	1 (1%)	8 (3%)
	HOT FLUSH	0 (0%)	1 (1%)	0 (0%)	1 (0%)
	HYPERTENSION	1 (1%)	2 (2%)	0 (0%)	3 (1%)
	HYPOTENSION	2 (2%)	1 (1%)	0 (0%)	3 (1%)
	ORTHOSTATIC HYPOTENSION	1 (1%)	0 (0%)	0 (0%)	1 (0%)
	WOUND HAEMORRHAGE	0 (0%)	0 (0%)	1 (1%)	1 (0%)

- 1.) Only treatment emergent events related to lipids are displayed.  
 2.) Subjects are only counted once within each body system and preferred term.